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Abstract
7HER2 enriched mammary breast cancer represents 15-25% of mammary carcinomas and
is associated to increased aggressiveness and worse prognosis. Advent of targeted
therapies against HER2 has improved 5-year survival up to 75%, nevertheless receptor
discordance, which is observed in 10.8% of metastasis,  as well as resistance to targeted
therapies render it a still challenging disease.
On the one hand, taking advange of a recently estabilished murine model of spontaneous
loss of HER2 expression, we sought to understand the underlying mechanism, to evaluate
role of trastuzumab and to identify identify druggable targets in HER2-negative
metastasis or relapses of HER2-positive tumors. The study of transcriptome of cell lines
with different HER2 expression has permitted us to identify pathways related to the
modulation of this more malignant phenotype, which appeared to be promoted by
trastuzumab. Some indications emerged for inhibition of PDGFR-B by sunitinib in
tumours which have lost HER2 expression.
On the other hand, a recently established collection of patient derived xenografts (PDX)
was used to obtain models of progression where to evaluate the effect of neratinib, a pan-
HER tyrosine kinase inhibitor. No abrupt loss of HER2 expression was registered in these
models. Collectively, our data, obtained in ER-/PR- HER2+ PDX, strongly indicate a
great and long-lasting efficacy of neratinib even in trastuzumab-resistance and after
progression and call for further evaluation of neratinib in advanced clinical settings. In
our PDX diagnosed as luminal B expressing HER2 (score 2+), neratinib alone had no
effect but synergized with tamoxifen and their combination tended to confer a little
survival benefit in vivo, thus underscoring the possible relevance of dual blockade in
tumors expressing both hormone receptors and HER2.
Introduction
9Breast cancer is estimated to be the second leading tumour diagnosed world-wide for both
sexes combined, with more than 2x106 new cases world-wide (11.6% of newly diagnosed
cancer). Worldwide, breast cancer is the most commonly diagnosed female cancer and
about 2.1 million newly diagnosed breast cancer cases have been estimated for 2018,
accounting for almost 1 in 4 cancer cases among women. Breast cancer is also the leading
cause of cancer death in more than 100 countries (Bray et al., 2018). Over the past
decades, breast cancer incidence has remained fairly stable, whereas mortality has
dropped of 38% thanks to early diagnosis and improvements in therapy. Indeed, most
breast cancer are local (>60%) or regional (>30%) at diagnosis, thanks to screening
programs, and 5-year survival rates has been 80-90% in 2006-2012 (Picture 1) (Siegel et
al., 2017). In Italy, breast cancer is the most frequently newly diagnosed cancer in women
of any age as well (29%), with 52800 estimated new cases in 2018. Breast cancer
represents the first oncological cause of death among women of all ages. 5- and 10-years
survival both exceed 80% (I numeri del cancro in Italia, 2018).
Breast cancer is hence a vast clinical problem as it pertains to a big cut of female
population all over the world. Breast cancer, though, is not a single entity but a multitude
of diseases and different subtypes with extremely different molecular characteristics,
response to therapies and prognosis (Yersal & Barutca, 2014).
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Picture 1. Epidemiology of breast cancer
(A) Estimates (rounded to the nearest 10) of new cases and deaths by sex for 10 most wide-spread
cancers in United States (US) for year 2017. Basal cell and squamous cell skin cancers and in situ
carcinoma except urinary bladder are excluded from the analysis.
(B) Incidence (rate per 105 people) of 10 principal cancers in women between 1975 and 2013 in US.
(C) Stage at diagnosis of female breast cancer in US between 2006 and 2014.
(D) Percent relative survival rates of female breast cancer in US between 2006 and 2014.
(Siegel et al., Cancer Statistics 2017)
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1.1 Breast cancer intrinsic subtypes
WHO (World Health Organization) offers a traditional classification of breast tumours
based on morphology, which includes few molecular elements (Sinn & Kreipe, 2013). At
present, grading and staging at diagnosis evaluate clinical parameters such as dimension,
lympho-nodal invasion, presence of metastasis, patient’s age and tumour grade;
moreover, ER (oestrogen receptor), PR (progesterone receptor) and HER2 are assessed by
immune-histochemical or molecular analysis as they are recognized as predictive and
prognostic markers in breast cancer (Schmidt et al., 2016).
In the past decades, thanks to -omic technics, a great effort has been performed to
classify breast cancer according to its molecular characteristics (Table 1).
The forefather paper by Sorlie and colleagues analysed gene expression of breast cancer
tissues by hierarchical clustering. Tumours could be classified into two principal clusters
according to ER expression. In ER negative cluster, tumours could be further classified in
basal-like, normal breast-like and ERBB2 overexpressing; ER positive tumours, also
defined luminal, could be distinguished in luminal A, B and C subtypes (Sorlie et al.,
2001). Later on, some subclasses rearrangement occurred, and the final and current
intrinsic subtypes were defined as luminal-A, luminal-B, HER2 enriched and basal-like.
Since 2011, St. Gallen consensus has adopted this classification in its recommendations
for adjuvant treatment of breast cancer. In the following decades, molecular profiling by
PAM50 or other microarrays provided a more accurate and reproducible technic to
identify intrinsic subtypes. Moreover, using the largest sample collection with extensive
genomic, transcriptomic and clinical annotation in existence, a scheme for classifying
breast tumours into 10 subtypes has been proposed, as well. This classification is based
on the pattern of copy number alternations (CNAs) which exert a concordant effect on
gene expression in cis (eQTLs). It is named IntClust owing to the clustering of tumours
based on the integration of genomic and transcriptomic data to find probable driver events
(Ali et al., 2014). Though more accurate and informative in patients’ stratification,
molecular profiling is expensive and not available for every patient. Hence, immune-
histochemical analysis and clinical-pathological parameters are still used in clinical praxis
as good surrogates for subtyping of breast cancer with a concordance of 80-90% to
clustering based on multi-gene analysis (Prat et al., 2015).
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Intrinsic
subtype
IHC
markers
Grading Prognosis Therapy Gene expression Mutations Sites of
metastasis
Luminal-A
50-60%
ER+
PgR+
HER2-
Ki-67 low
HER2+
6.3-7.8%
Low: few nuclear
pleomorphism and low
mitotic activity
Good: low
relapse rate
Endocrine
therapy
Cytokeratin (CK8 and 18)
Luminal genes downstream
to ER: ER1, LIV1, X-BP1,
ZIP6, SLC39A6, HGF3A,
TFF3, FOXA1, BCL2, HER3
and HER4
TP53 12%
MAP3K1 45%
PI3KCA 13%
GATA3 14%
Low mutational
burden
Brain 8%
Liver 29%
Lung 24%
Bone 67%
Visceral 28%
Luminal B
15-20%
ER+
PgR+/-
HER2-
Ki-67 high
HER2+
16.4-20.8%
High: ki-67 high, various
aneuploidies
Intermediate:
higher relapse
rate and lower
survival
Less responsive
to endocrine
therapy than
luminal A;
chemotherapy
Proliferation-related genes:
v-MYB, GGH, LAPTMB4,
NSEP1, CCNE1, AURKA
TP53 29%
MAP3K1 29%
PI3KCA 5%
GATA3 15%
Iper-methylation
Brain 11%
Liver 32%
Lung 24%
Bone 71%
Visceral 35%
HER2
enriched
15-25 %
ER-
PgR-
HER2 +
High: high proliferative
index and genomic
instability
Poor, in absence
of targeted
therapies
HER2 targeted
therapies in
(neo)adjuvant
setting+
chemotherapy
(doxorubicin)
HER2 and pHER2 and
downstream related genes
GRB7 and other genes on
HER2 amplicon
TP53 72%
PI3KCA 39%
Brain 29%
Liver 44%
Lung 37%
Bone 60%
Visceral 32%
Basal-like
8-37%
ER-
PgR-
HER2-
HER2+
2.1-17.4%
High: high proliferative
index, poor tubule
formation, presence of
necrotic or fibrotic zones,
pushing borders, abundant
lymphocytic infiltration,
medullary features
Poor: frequent
metastasis,
younger patients
Chemo- and
radiotherapy
Myoepithelial markers:
CK5, 14 and 17
Laminin, P-cadherin, fascin,
caveolin 1-2, αβ-crystallin
and EGFR
BRCA-1
TP53 80%
PI3KCA 9%
Hypo-
methylation
Brain 25%
Liver 21%
Lung 43%
Bone 39%
Visceral 30%
Table 1. Breast cancer intrinsic subtypes
The table reports histological, clinical and molecular features of breast cancer by intrinsic subtype (Modified from Sorlie et al., 2001; Kennecke et al., 2010; Yersal &
Barutca, 2014; Hoadley et al., 2014; Prat et al., 2015; Iancu et al., 2017).
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1.2 Luminal breast cancer
Luminal tumours are named according to their up-regulated expression of genes related to
epithelial and luminal differentiation. Altogether, they represent 75% of breast cancers
(Yersal & Barutca, 2014) and show a tendency to better prognosis with respect to non-
luminal tumours.
Luminal A tumours are the most common intrinsic subtype of breast cancer (50-60%).
The low ki-67 (mitotic index inferior to 14%) distinguishes them from luminal B subtype.
Phenotypically, luminal A tumours are characterized by low histological grade, low
degree of nuclear pleomorphism and low mitotic activity; they also express luminal
cytokeratin 8 and 18. At molecular level, besides the expression of ERα, they also express
high levels of ER1, GATA binding protein 3, X-box binding protein 1, trefoil factor 3,
hepatocyte growth factor 3α and oestrogen-regulated LIV1, BCL2, erbB3 and erbB4. At
the DNA level, luminal A tumours show a low genomic instability which is mirrored by
the low number mutations and chromosomal aberrations. TP53 is rarely found mutated
(12%), whereas MAP3K1 and PI3KCA mutations are more common (45% and 13%,
respectively). Clinically, patients with luminal A breast cancer have good prognosis and
significantly lower relapse rates than other subtypes. Recurrences are to be found mainly
in bone. Gold standard therapy for this subtype is endocrine therapy with either SERMs
(selective oestrogen receptor modulators) such as tamoxifen, or inhibitors of aromatase
which convert androgens in oestrogens, or up-stream block of ipothalamus-ipophysis axis
with LH-RH analogues. Luminal A tumours are so responsive to endocrine therapy that
adjuvant therapy does not require chemotherapy, but only tamoxifen given for 5-10 years
(Sorlie et al, 2001; Yersal & Barutca, 2014; Hoadley et al., 2014; Prat et al., 2015; Iancu
et al., 2017).
Luminal B tumours comprise 15-20% of breast cancers. They show lower expression of
genes related to ER compared to luminal A tumours and higher proliferative index,
accompanied by a higher expression of proliferation-related genes such as v-MYB,
gamma glutamyl hydrolase, lysosome-associated transmembrane protein 4-beta, nuclease
sensitive element binding protein 1 and cyclin E. AURKA (aurora kinase A) and genes
related to signalling down-stream growth factor receptors are found up-regulated in this
subtype, as well. At DNA level, conversely to what observed in luminal A, luminal B
tumours are more frequently mutated in TP53 (29%) yet less frequent mutations are
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detected in PI3KCA (5%) and MAP3KI (29%). Moreover, methylation pattern of luminal
B cancers is altered, and hyper-methylation is registered in up to 8% of cases. Prognosis
is worst for this subtype in the first 5 years after diagnosis. Metastasis are frequently
found in bone, as in luminal A tumours. Luminal B tumours are less sensible to endocrine
therapies but more to chemotherapy due to their increased mitotic index. Hence, in this
subtype endocrine therapy is more often accompanied by chemotherapy (Sorlie et al,
2001; Yersal & Barutca, 2014; Hoadley et al., 2014; Prat et al., 2015; Iancu et al., 2017).
Of note, intrinsic subtypes in breast cancer are not to be intended as airtight
compartments and exceptions exist. For example, a quote of luminal A (6.3-7.8%) and B
tumours (16.4-20.8%) overexpress HER2 (Prat et al., 2015). It is still under scientific
debate whether a new subtype of triple positive breast cancer, expressing both ER/PR and
HER2 at high levels, actually exists. A peculiar behaviour of these tumours has indeed
been noticed in clinical trials and in the clinic: triple positive tumours show an increased
tendency to develop resistance to therapy. This could partly be explained by the fine
interplay existing by ER/PR and HER2 signalling pathways, which are alternatively up-
regulated when the other pathway is inhibited. Research is still ongoing to determine
whether these tumours benefit from a dual approach with endocrine therapy combined
with anti-HER2 agents (Iancu et al., 2017).
1.3 HER2-enriched
HER2 enriched tumours account for 20-25% of breast cancers. HER2 overexpression is
an independent factor of worst prognosis by itself, conferring aggressiveness at both
biological and clinical levels. Phenotypically, HER2-enriched tumours are characterized
by HER2 amplification and overexpression and absent or low ER/PR, high proliferative
index, nuclear and histological grade. Gene expression is dominated by genes linked to
HER2 overexpression or found on the same amplicon on 17q21; luminal and basal-like
typical genes are expressed at low to intermediate level. Genomic instability is observed
in HER2-enriched tumours, probably due to up-regulation of APOBEC3B which encode
a deaminase converting cytidine to uracil. TP53 is frequently found mutated (72%) as
well as PI3KCA (39%). Without targeted therapies, prognosis of HER2 enriched tumours
is extremely inauspicious, with high recurrences rate often in the brain. Therapy is
primarily based on HER2-targeting agents; furthermore, HER2 enriched tumours show a
marked sensibility to doxorubicin, due to presence of its target (TOPOIIA) in HER2
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containing amplicon (Sorlie et al, 2001; Yersal & Barutca, 2014; Hoadley et al., 2014;
Prat et al, 2015; Iancu et al., 2017).
As previously observed, a quote of HER2 overexpressing tumours may fall in other
intrinsic subtypes. It should be noted that HER2 enriched subtype embraces tumours with
very different levels of HER2 amplification and overexpression; this heterogeneity may
affect prognosis as well as response to therapies. Moreover, not every up-regulation of
HER2 detected by microarray is translated at protein level and in turn not every HER2
overexpressing tumour by immunohistochemistry will be assigned to HER2 enriched
intrinsic subtype (Prat et al., 2015).
1.4 Basal-like
Basal-like tumours are extremely different in morphological and molecular characteristics
from the other subtypes. Real proportion of basal-like tumours is difficult to calculate, as
they are often diagnosed as big undifferentiated tumours and often fall out of breast
cancer statistics; however, they are estimated 8-37% of all breast cancers. Phenotypically,
basal-like cancers have high histological and nuclear grade together with high mitotic and
proliferative indexes, poor tubule formation, presence of necrotic or fibrotic zones,
pushing borders, abundant lymphocytic infiltration, medullary features. Their expression
profile lacks luminal genes and is in turn enriched in basal genes, like cytokeratin 5, 14,
17, adhesion molecules such as laminin, P-cadherin, fascin, caveolin 1 and 2, αβ-
crystallin, and other membrane molecules (fatty acid binding protein 7 and epithelial
growth factor receptor 1). Commonly deregulated pathways are integrin, MAPK, PI3K-
Akt and NF-kB, but the landscape of basal-like breast cancers is extremely variegated. At
DNA level, they show abundant genomic instability with frequent loss of function
mutations in TP53 and Rb; moreover, BRCA1 mutated breast cancer often show a basal-
like phenotype. Prognosis of these aggressive tumours is exceptionally poor, even worsen
by lack of therapeutic targets. Metastasis in this subtype are common and target
principally lung and brain (Sorlie et al., 2001; Yersal & Barutca, 2014; Hoadley et al.,
2014; Prat et al., 2015; Iancu et al., 2017).
In the diagnosis praxis, basal-like tumours are recognized as triple negative tumours,
since they express neither ER/PR nor HER2 receptors. It should be however noted that
some basal-like tumours express HER2 (2.1-17.4%) and that not every triple negative
tumour can be assigned to the basal-like subtype. At least two other sub-clusters are
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reported in literature, such as claudin-low and normal-breast like. The former is an
extremely aggressive subtype characterized by absence of adhesion molecules forming
tight junctions such as claudin, occludin and E-cadherin, by features of epithelial-to-
mesenchymal transition (EMT) and cancer stem cells. Normal breast-like cancers are still
triple negative, but cluster together with normal and benign adenoma samples; their real
occurrence and biological significance is still debated (Prat et al., 2015).
1.5 New insights in breast cancer aetiology
An open question is how different the 4 breast cancer subtypes are and more importantly
whether all breast cancers stem from a single progenitor or not.
A principal component analysis revealed that transcription profiles of luminal and HER2
enriched subtypes are mutually similar. In contrast, basal-like tumours are more similar to
squamous cell lung carcinomas than to the other breast cancer subtypes and should hence
be regarded as a single molecular entity (Prat et al., 2015).
A bimodal distribution of breast cancer incidence has been noted with two peaks at 50
and 70 years. Dissecting this difference by intrinsic subtype, it was revealed that ER
positive and ER negative tumours show an independent bimodal incidence with opposite
trends. ER negative cancers had a major incidence peak at 50 years, whereas ER positive
tumours had more frequently a later onset (Anderson et al., 2014).
Following these and other observations, Anderson and colleagues suggested a major
division between basal-like and luminal breast cancers, with HER2 enriched tumours
being luminal cancers with HER2 expression as a plus. In this model, a transformation
event can occur either in a progenitor cell committed to luminal differentiation giving rise
to a luminal tumour (A, B or HER2 enriched) or in a basal/myoepithelial committed cell
originating a basal-like tumour (Picture 2).
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Picture 2. Aetiology of breast cancer
The cartoon illustrates the hypothesis of breast cancer of luminal (A, B or HER2-positive) and non-
luminal (basal-like) cancer originating by transformation event (lightning bolts) in differently
committed cells (Anderson et al., 2014). HER2E= HER2 enriched
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2. Role of HER2 in breast cancer
HER2 enriched tumours account for 15-25% of breast cancers. HER2 was first identified
as a proto-oncogene whose amplification was an independent factor of worse prognosis,
namely shorter relapse-free and overall survival, in 1987 in a cohort of 189 breast cancer
patients (Slamon et al., 1987; Menard et al., 2004). Since then, extensive research has
deepened our knowledge of the mechanistic role of HER2 in oncogenesis and numerous
targeted therapies against HER2 have been developed, ameliorating prognosis. Currently,
life expectance for metastatic HER2-positive breast cancer is 5 years and 75% of newly
diagnosed patients achieve a pathological complete response (Loibl & Gianni, 2017).
Still, HER2-positive breast cancer presents challenges for clinicians and researcher,
mainly due to high rates of intrinsic and acquired resistance to HER2 targeted therapies
and metastasis to the brain.
2.1 Biology of ErbB-HER receptor family
The HER family (also called ErbB or epidermal growth factor receptor family) comprises
four transmembrane receptor tyrosine kinases, EGFR (or HER1), HER2, HER3, and
HER4 (Eccles, 2011; Nuciforo et al., 2015; Hsu & Hung, 2016). As many other receptor
tyrosine kinases, these receptors are involved in many essential developmental processes
such as differentiation, cell proliferation, motility, wound healing, tissue regeneration and
apoptosis.
All receptors in HER family are membrane-anchored proteins and share a similar
structure, made up of 4 domains. An extra-cellular (ECD) domain responsible for ligand
binding (LD1 and LD2) and dimerization (CR1 and CR2), a membrane-spanning domain
and an intracellular domain (ICD) responsible for auto-phosphorylation and triggering of
down-stream signalling cascade (Roskoski, 2014; Bazley & Gullick, 2005).
In absence of a ligand, receptors lay interspersed in the plasma membrane in close
conformation, with the dimerization domain blocking ligand binding domain in the
receptor monomers. Upon ligand binding, receptors switch to an open conformation
where dimerization domain is accessible for homo- or hetero-dimerization with other
HER receptor monomers (Bazley & Gullick, 2005). Active receptors cluster in the
membrane in complexes involving up to 106 receptors. Moreover, HER receptors have
been demonstrated to interact with other receptor tyrosine kinases such as IGF-1R
(insulin growth factor receptor 1) and c-MET as well as adhesion molecules, i.e. integrins
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and tetraspanins (Eccles, 2011). These cross-links between receptor tyrosine kinases
belonging to different families may also provide a ligand-independent way of activation
of HER receptors (Stern, 2008).
HER2 and HER3 represent exceptions to this model. HER2 indeed is not able to assume a
close conformation and shows a very low affinity for ligands: this receptor is therefore
always accessible for dimerization with other HER receptors, regardless of ligand. HER3,
in turn, lacks tyrosine kinase activity and is therefore obliged to form heterodimers upon
ligand binding. Hence, HER2 and HER3 homo-dimers are not active and these receptors
are preferred partner of dimerization of the other HER receptors.
Up to date, 10 different ligands of HER receptors have been identified, which are
produced by protease cleavage of membrane-anchored precursors by ADAM protease.
EGF (epithelial growth factor), TNF α (tumour necrosis factor α), amphiregulin (AR) and
epithelial mitogen (EPGN) bind only to HER1; betacellulin (BCN), heparin binding
epithelial growth factor (HB-EGF) and epiregulin (EPR) bind both HER1 and HER4;
lastly, heregulins or neuregulins (NRG) bind both HER3 and HER4 (NRG-1 and -2) or
HER3 only (NRG-3 and -4) (Moasser et al., 2007). Upon ligand binding, HER receptor
monomers could theoretically form 10 different dimers, but not all of them are equally
active (Eccles, 2011). Heterodimers involving HER2 and HER3 result the most active
because of high affinity binding to dimerization partner and to ligand (HER3 only). They
are followed by other heterodimers containing HER2, non-HER2 heterodimers and lastly
homodimers of HER1 (the only one active homodimers) (Eccles et al., 2011).
Other than signalling mediated by their tyrosine kinase activity (see paragraph 2.4), all
ErbB-HER receptors can translocate to the nucleus and directly control transcription of
target genes, interact with other transcription factors and alter DNA structure (Hsu &
Hung, 2016).
HER family signalling may appear redundant, but the variety of ligands and possible
dimerization partners leads to unique and specific signalling pathway down-stream. The
type and amplitude of activated downstream signalling cascades are a co-function of
which receptors are expressed by a particular cell, the number of receptors expressed, and
the amount and type of ligand that stimulates the cell (Harari and Yarden, 2000): HER1
and HER4 have 100 different molecular interactors, whereas HER2 and HER3, being
mock receptors, show fewer interactors mostly linked to their tyrosine kinase activity (i.e.
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HER3 present copious docking sites for Akt activating subunit, p85) (Moasser, 2007;
Sergina & Moasser, 2007; Hynes & MacDonald, 2009).
Signalling of HER receptors is terminated by ligand-dependent endocytosis, regulated by
c-Cbl (Cbl proto-oncogene, E3 ubiquitin protein ligase) which has greater affinity for
HER1 rather than HER2 and no affinity for HER3 and HER4 (Yarden, 2001).
2.2 ErbB-HER receptors in cancer
Given their role in cell proliferation, differentiation and motility, it is self-evident that an
aberrant expression of ErbB-HER receptors may lead to cancer and in the last decades a
leading role has been proposed for many of these receptors in initiating and promoting
solid tumours’ growth (Bazley & Gullick, 2005; Arteaga & Engelmann, 2014).
Overexpression of EGFR has been observed in breast, lung, colorectal, oesophageal
cancers, and glioblastomas. Its up-regulation can be due to amplification, as in some triple
negative breast cancers. Another mechanism of HER1 activation is represented by
deletion of some exons in its ECD, which leads to an always open and signalling
conformation: deletions of exons 2-7 are found in 40% of glioblastomas (Arteaga &
Engelmann, 2014). Moreover, EGFR can harbour gain-of-function mutations, which are
reported in 10–35% of lung cancers. In breast cancer, EGFR is rarely mutated, but its
overexpression is observed in 15–30% of patients, primarily in basal-like and triple
negative tumours, where it associates with large tumour size and poor clinical outcomes
(Hsu & Hung, 2016). Targeted therapies against HER1 include monoclonal antibodies
(cetuximab) and tyrosine-kinase inhibitors (afatinib, erlotinib and gefinitib). These drugs
are in current clinical praxis for lung tumours and glioblastomas showing overexpression
of EGFR; their implementation in triple-negative breast cancer is under evaluation.
Other than in breast cancer, HER2 is found amplified in gastric and oesophageal tumours.
HER2 mutations in breast cancer are rare (2.8%), but they can be detected in other
carcinomas such as ovary, endometrium, lung, head&neck, colon, liver, bladder and
glioblastomas (Yan et al., 2014; Connell and Doherty, 2017). Target therapies against
HER2 comprise trastuzumab, trastuzumab-DM1, pertuzumab, lapatinib and neratinib and
will be discussed later (see paragraph 3).
HER3 has no oncogenic potential by itself because of lack of tyrosine kinase activity, but
it is required for oncogenesis driven by other HER receptors: HER3 knock-out mice fail
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to develop mammary tumours despite HER2 overexpression (Mujoo et al., 2014). It is
often co-expressed with HER2 and alterations in its copy number have been reported in
28% of HER2-positive breast cancers. Its mutations are rare and sporadically observed in
breast and gastric cancer (Arteaga & Engelmann, 2014; Hsu & Hung, 2016).
HER4 has a controversial role in breast cancer, where some authors report its tumour-
suppressing activity and others its oncogenic potential. Mutations of HER4 have been
found in melanomas, medulloblastomas, lung and non-small cell lung carcinomas
(Arteaga & Engelmann, 2014; Hsu & Hung, 2016).
A further mechanism explaining oncogenic potential of ErbB-HER receptors is
represented by excessive production of their ligands due to mutations or aberrant
trafficking (Arteaga & Engelmann, 2014).
2.3 HER2 patho-physiological role
HER2 is principally involved in development and maintenance of cardiac and nervous
epithelia, other than of the mammary gland. HER2 knock-out mice face a premature
intra-uterus death, highlighting HER2 crucial role in embryogenesis: HER2-HER4
dimers activated by neuregulins are involved in development of cardiac trabeculae,
HER2-HER3 dimers are in turn involved in correct differentiation of Schwann cells and
formation of peripheral ganglia (Emde et al., 2012). After birth HER receptors assume a
prominent role in normal development of the mammary gland. During puberty, signalling
from HER1-HER2 dimers promote invasion of fat pad by out-branching mammary tubes.
In the mature mammary gland, HER2 controls mammary ducts morphology and density
orchestrating formation of terminal end buds. During pregnancy, HER2 promotes
formation of alveolar tubes (Eccles, 2011).
As demonstrated in mice transgenic for human HER2 expression and in cell lines
transduced with this gene, HER2 amplification is a necessary and sufficient condition to
induce tumorigenic transformation (Moasser et al., 2007). Amplification occurs at DNA
level, where 25-50 copies of the oncogene can be found in transformed cells, and
exponentially augments both expression at RNA level (40-100 times with respect to
normal cells) and number of receptor monomers on cell surface (up to 2x106 receptors per
cell). It is self-evident that this amplification not only increases tyrosine kinase activity of
HER2 as a point mutation would, but also provokes structural changes in the membrane
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and alters signalling downstream all ErbB-HER receptors which concur together in
oncogenesis.
HER2 is the preferred dimerization partner of all other HER receptors and forms stronger
and more persistent dimers. High density of HER2 monomers promotes formation of
HER2-containing homo- and heterodimers, thus intensifying signalling down-stream all
HER receptors. Increased homo-dimerization and dimers’ clustering disrupt membrane
structure, especially at tight junctions, causing a loss of cell polarization and unordered
proliferation of epithelial cells. Moreover, HER1-HER2 dimers promote cell motility by
signalling down-stream of Akt, Ras and protein lipase C (PLCγ). Hence, HER2
amplification completely disrupts tissue architecture (Moasser et al., 2007).
HER2 exists not only as full-length protein but also as isoforms, lacking C-terminus, N-
terminus or internal exons. These isoforms, like Δ16 and p95HER2, have often been
linked to increased aggressiveness and resistance to targeted therapies (Castiglioni et al.,
2006; Sperinde et al., 2010; Arribas et al., 2011; Marchini et al., 2011; Castagnoli et al.,
2017; Palladini et al., 2017). HER2 amplification leads to a parallel increase in the
expression of these isoforms, as well.
HER2 can translocate to the nucleus and directly regulate target genes, such as COX2
(cycle-oxygenase 2), VEGF-A (vascular-endothelial growth factor A), Stat3 (signal
transducer and activator of transcription 3) and CXCR4 (chemokine C-X-C motif
receptor 4). As observed for trans-membrane isoforms, nuclear HER2 is increased due to
amplification as well and results in increased expression of target genes (Moasser et al.,
2007).
HER2 amplification, moreover, affects the rate of ligand release from active dimers and
slows down receptor recycling and internalization, making signalling even more
persistent (Harari & Yarden, 2000; Prenzel et al., 2011).
HER2 is not the only amplified gene, but part of a bigger amplicon conserved among
HER2 enriched tumours and centred on HER2. This amplicon (17q12-21; minimum size
280 Kb) comprises 10 transcribed genes, such as GRB7 (growth factor receptor-bound
protein 7) directly linked to HER2 function, MLN64 involved in cholesterol trafficking,
TOPO II A (topoisomerase II A), PNMT, MGC9753 and MGC14832 which are all
amplified together with HER2.
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2.4 Alterations in HER down-stream signalling pathways
Physiologically, the principal signalling pathways activated by HER dimers are
phosphatidylinositol 3-kinase (PI3K), Ras, phospholipase Cγ (PLCγ), and Janus-activated
kinase (JAK) (Picture 3).
Signalling through PI3K is generally due to hetero-dimerization of any HER receptor
with HER3, which harbours 6 docking sites for the activating subunit of PI3K, p85. This
pathway is mostly activated by HER2-HER3 heterodimers though, since HER3 represents
the preferred HER2 ligand. The catalytic subunit of PI3K, p110 converts PIP2
(phosphatidylinositol 4,5 -bisphosphate) in IP3 (inositol 1,4,5 trisphosphate), which in
turn activates Akt leading to cell survival and inhibition of apoptosis. Indeed, Akt inhibits
BAD (BCL2-associated antagonist of cell death), FKHR and p27 which would stop cell
cycle and induce apoptosis. In turn, Akt activates mTOR, NF-kB, FOXO and GSK3β
which mediate further proliferative and anti-angiogenic effects (Eccles, 2011).
Ras signalling activation is mediated by docking of the adapter proteins Grb2 (Growth
factor receptor-bound protein 2) and guanine exchange factor, Sos (Son of seven less),
directly or through other Shc (Src homology domain) adaptor to the docking sites on
HER1or HER2 ICD. Binding of these adaptor proteins recruits Ras GTP-binding protein
and results in Ras activation, which triggers the kinase cascade that activates Raf, MEK,
and ERK. As a final result, transcriptional factors are phosphorylated and translocate to
the nucleus, where they regulate cell proliferation and motility through up-regulation of
ELK1 and, MYC and Jun/Fos (Emde et al., 2012).
PLCγ is activated by heterodimers comprising HER1 only. Once docked at
phosphorylated receptors and activated, the enzyme breaks PIP2 to yield IP3, which
induces transient increase in intracellular calcium and DAG (1,2-diacylglycerol), which
functions as a co-activator of protein kinase C. Activation of this pathway results in
transcriptional activation of Jun/Fos (Eccles, 2011).
HER1 and HER4 can bind to and directly activate signal transducer and activator of
transcription (STAT) proteins via the Sh2 domain. Once active, STAT proteins homo-
and hetero-dimerize and translocate into the nucleus to drive expression of specific target
genes involved in proliferation, differentiation, and survival.
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Since HER2 is the preferential partner of other HER receptors, it is self-evident that all
pathways down-stream to HER family are up-regulated in HER2 enriched breast cancer.
HER2 and HER3 form the strongest dimers, hence HER2 amplification in breast cancer
primarily results in activation of PI3K pathway down-stream HER3. Activation of PI3K-
Akt pathway aberrantly controls cell survival, dimension, response to nutrients, glucose
metabolism, epithelial to mesenchymal transition (EMT), motility, genome stability and
angiogenesis (Moasser, 2007).
HER receptors are rich in docking sites for adaptor proteins containing PTB
(phophoproteinase binding) or Sh2 domains, leading to Src protein activation down-
stream. Their role in mammary carcinogenesis still needs to be clarified. Their inhibition
in a human HER2-positive cell lines blocks aggressive clones with metastatic potential,
leading to hypothesize a role of Src proteins in loss of cell polarity and cell-cell adhesion
with consequent anchorage-independent growth. Moreover, Src proteins can
phosphorylate HER2 in Tyr877 increasing its affinity to HER3 (Moasser et al., 2007).
Signalling down-stream PI3K phosphorylates p27kip1, sequestering it in the cytoplasm,
and HER2 further modulates its action through MAPK signalling pathway; HER2
overexpression thus alters cell cycle control at G1/S checkpoint. Moreover, cyclin D1, E
and cdk6 (cyclin dependent kinase 6) are often hyper-expressed in HER2 enriched
tumours. Indeed, transgenic mice for HER2 expression and knock out for cyclin D1 or
cdk4 or p16 fail to develop mammary tumours (Moasser et al., 2007).
Many other pathways down-stream HER receptors result altered in HER2 overexpressing
cancer, many of them promoting a metastatic phenotype. They include modulation of
PKC-α, FAk (Focal Adhesion kinase), TGF-β, integrin β4 and α, and of
metalloproteinases 2 and 9 (MMP-2 and -9) all contribute to this phenotype (Moasser et
al., 2007).
Last but not least, overexpression of HER2 aberrantly modulates angiogenesis, leading to
formation of scarcely organized and often fenestrated vessels. Indeed, HER2 directly up-
regulates transcription of VEGF-A and HIF-α; moreover, it enhances their translation
through P706K kinase, down-stream to Akt signalling. COX-2 is also up-regulated by
nuclear HER2: it again enhances secretion of VEGF and of eicosanoids, which activate
endothelial cells protecting them from apoptosis (Alameddine et al., 2013).
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Picture 3. Signalling of HER2 receptor family
Figure shows HER receptor interactions upon ligand binding and elicited down-stream pathways (Yarden &
Sliwkowski, 2001).
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3. HER2 targeted therapies
HER2 targeted therapies are offered as standard of care to all patients diagnosed with
HER2-positive breast cancer. According to St. Gallen consensus and ASCO/CAP
recommendations 2013, HER2-positive cancers are defined as 1) evidence of HER2
protein overexpression measured by immunohistochemistry IHC3+ status and complete
staining in at least 10% of cells, or 2) by fluorescence in-situ hybridisation (FISH)
measurement of a HER2 gene copy number of six or more or a HER2/CEP17 ratio of 2·0
or greater (Loibl and Gianni, 2017). HER2 targeted agents exploit two different
mechanisms of action: on the one hand, HER2 is used as a target to convey molecules
with cytotoxic properties (antibodies or antibody-drug conjugates) specifically to the
tumour; on the other hand, tyrosine kinase inhibitors directly dampen oncogenic
signalling downstream HER2 (Escrìvia-de-Romani et al., 2018). Clinicians currently
dispone of 5 drugs targeted against HER2, trastuzumab, the forefather of anti-HER2
agents, trastuzumab-DM1, pertuzumab, lapatinib and neratinib to be used in different
clinical settings (table 2).
3.1 Trastuzumab: mechanism of action and resistance
The current standard of care for HER2-positive early breast cancer includes trastuzumab
(with or without pertuzumab) and chemotherapy given either before or after surgery
(Loibl and Gianni, 2017). Trastuzumab is a humanized monoclonal antibody which
targets HER2 ECD in domain IV (the nearest domain to the membrane); year 2018 marks
20 years since consent to its commercialization by FDA. Approval of trastuzumab was
granted following several trials determining a benefit of adding trastuzumab to
chemotherapy both in neoadjuvant and adjuvant setting. HERA trial showed 1 year of
adjuvant trastuzumab was associated with significant improvements in both 10-year
disease-free survival (DFS; 69% vs 63%; HR 0.76) and 12-year of overall survival (OS
79% vs 73%; HR 0.74) compared to observation (Baselga et al., 2017). Other trial
demonstrated no additional benefit in prolonging treatment with trastuzumab for 2 years.
NOAH trial confirmed these results in neoadjuvant setting, where addition of trastuzumab
to chemotherapy significantly improved rate of pathologic complete response (pCR) and
5-year event-free-survival (EFS 58% vs 43%; HR 0.64) (Baselga et al., 2017).
Albeit its wide-spread use in clinical practice, trastuzumab mechanisms of action still
need to be completely understood. Known effects of trastuzumab are reported below
(Wong & Lee, 2012):
27
 As an antibody, trastuzumab elicits antibody-dependent cell-mediated cytotoxicity
(ADCC) through binding to FcγR on effector NK (natural killer) cells, which
lysate cells bound to trastuzumab;
 Trastuzumab inhibits HER2 shedding and decreases blood levels of p95HER2,
which have been linked to a more aggressive tumoral phenotype;
 Trastuzumab inhibits down-stream signalling and progression through cell cycle
by up-regulation of PTEN and p27kip1 and simultaneous down-regulation of PI3K
and Akt;
 Trastuzumab inhibits hetero-dimerization of HER2 creating a steric hindrance and
induces apoptosis;
 Trastuzumab normalizes intra-tumour vasculature enabling a better drug delivery;
Trastuzumab has demonstrated efficacy in early breast cancer, but still a significant
proportion of patients will eventually progress. Phase III trials evaluating trastuzumab
reported different rates of progression, varying from 28.8% at 10-years follow-up in
HERA trial to 42% at only 5 years follow-up in NOAH trial. More recent trials have
registered and improvement up to 5-year DFS of over 85%. Even if it is difficult to
correctly estimate proportion of patient relapsing after first-line trastuzumab, these data
clearly indicate an unmet need to understand mechanisms of acquired resistance to
trastuzumab. Moreover, heterogeneity in HER2-positive tumours should be considered as
some patients show an intrinsic resistance to trastuzumab despite being diagnosed with an
HER2-positive disease. Research is thus ongoing to identify predictive markers of
response to therapy other than HER2 and alternative therapeutic approaches in
trastuzumab-resistant patients (Baselga et al., 2017).
Acquired resistance to trastuzumab can be due to factors intrinsic to the target, activation
of compensatory pathways or to host-related factors.
It is self-evident that alterations such as mutations of HER2 can prevent trastuzumab
binding, thus limiting its efficacy. Mutations are rare in HER2, but emergence of isoforms
lacking epitope bound by trastuzumab also frustrate or limit treatment efficacy.
Moreover, trastuzumab binding to HER2 can be sterically hindered by up-regulation of
mucin-1 or -4. Up-stream up-regulation of HER ligands can also outweigh trastuzumab-
mediated inhibition.
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Once signalling through HER2 ECD is pharmacologically inhibited, cells try to
counteract this by intracellular pathways of ligand-independent activation of HER2. This
receptor can indeed be trans activated by hetero-dimerization with any other activated
HER receptor, as well as IGF-1R, MET and EphA2. Moreover, TGFβ can mediate
resistance to trastuzumab by up-regulating ADAM17 protease, which cleaves HER
ligands from the membrane, and thus augmenting their local concentrations. Activating
mutations in pathways down-stream HER2 or re-activation of ER pathway can
counterbalance trastuzumab action as well.
Lastly, resistance to trastuzumab can be due to alteration of tumoral microenvironment.
One hallmark of cancer is deregulation of apoptosis machinery, which is required for
trastuzumab inhibitory action: alterations in BIM, survivin, cyclins or p27kip1, frequently
found in HER2-positive tumours, can allow cells to escape apoptosis again impeding
trastuzumab action. Trastuzumab enhances receptor degradation; thus, any miss-
regulation of endocytosis can dampen its efficacy. Trastuzumab action is also mediated
by ADCC, so any down-modulation of immune system due to tumour immune-
suppressive properties or to host polymorphisms or mutations in ADCC machinery can
cause resistance to trastuzumab (Rexer & Arteaga, 2012; Escrìvia-de-Romani et al.,
2018).
Of note, trastuzumab displays a well-known cardio-toxicity which limits its usage in
patients with high cardiac risk.
Trastuzumab patent has expired with the consequence of many biosimilar being tested in
clinical trials. Results appear favourable and trastuzumab-biosimilar are expected soon to
enter in the clinical praxis, providing an alternative and hopefully less expensive choice
of treatment.
Research is ongoing to improve trastuzumab, as well. It has been reported that
polymorphisms in FcγR can influence trastuzumab binding and the magnitude of ADCC
elicited. Margetuximab was designed to improve trastuzumab binding to low-affinity
receptors and contemporarily decrease trastuzumab affinity for inhibitory receptor
FcγRIIB. Combination of margetuximab and chemotherapy is now being directly
compared to trastuzumab plus chemotherapy in the pivotal phase III trial SOPHIA
(Escrìvia-de-Romani et al., 2018) (Table 3).
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3.2 Trastuzumab-DM1, Pertuzumab and other antibodies
Trastuzumab-DM1 conjugates the antibody with emtansine, a potent inhibitor of
microtubule polymerization, which is driven to the tumour cells by trastuzumab. Thus,
this drug improves therapeutic index minimizing exposure of normal tissues (Loibl and
Gianni, 2017). T-DM1 was tested in the two phase III TH3RESA and EMILIA trials
enrolling patients with advanced breast cancer progressed after trastuzumab; both trials
reported a statistically significant benefit in progression free survival (PFS) with respect
to lapatinib+capecitabine or treatment of physician’s choice. MARIANNE trial was
designed to test T-DM1 action alone or combined with pertuzumab in neoadjuvant
setting; unfortunately, the two drugs did not show additive action nor improvement in
PFS with respect to trastuzumab and a taxane. So, despite its favourable safety profile and
better quality of life of patients treated with T-DM1, this drug is currently approved only
in metastatic breast cancer patients pre-treated with trastuzumab and taxane. Of note,
despite involving a big antibody-drug complex, some activity of T-DM1 on brain
metastasis has repeatedly been reported (Loibl and Gianni, 2017; Hurvitz et al., 2017).
Pertuzumab is a second monoclonal antibody targeting HER2 in the dimerization domain;
indeed, HER2-driven transformation and signalling requires hetero-dimerization. Its
activity has been documented in first line setting by CLEOPATRA phase II and
NeoSphere phase III trial. Both of them showed superiority in terms of response rates and
overall as well as progression free survival of regimens adding pertuzumab to
trastuzumab and docetaxel and minimal increase in toxicity, with respect to either single
drug. These trials granted approval for pertuzumab in first line treatment in HER2-
positive breast cancer. There are currently no indications for a prosecution of treatment
with pertuzumab beyond progression (Loibl and Gianni, 2017; Hurvitz et al., 2017).
Bi-specific antibodies target multiple epitopes in order to simultaneously affect different
molecules. ZW25 targets two distinct epitopes on HER2 and appears to improve binding
affinity and receptor degradation. MCLA-128 targets both HER2 and HER3 and has
shown promising activity in a phase I trial. Simultaneous targeting HER2 and CD3 with
ertumaxomab appears promising as it has demonstrated both immune-stimulatory and
anti-tumour activity in a trial, enrolling patients with HER2-expressing advanced solid
tumours. Moreover, encouraging data on a new bispecific antibody simultaneously
targeting p95HER2 and CD3ε have recently been reported in a preclinical study on
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mammary patient derived xenografts (Ruiz et al., 2018; Hurvitz et al., 2017; Escrìvia-de-
Romani et al., 2018) (Table 3).
New antibody-drug conjugates are in the pipe-line, as well. SYD 985 combines
trastuzumab with a prodrug, DUPA SYD 986, which is activated by proteasomal cleavage
in lysosomes or in the tumoral microenvironment becoming a potent alkylating agent. Its
efficacy in second-line is being evaluated in TULIP phase III trial. DS-8201 combines
trastuzumab with a topoisomerase II inhibitor and is showing promising activity in phase
I and II trials (Escrìvia-de-Romani et al., 2018).
Other strategies to deliver chemotherapy to HER2-positive cells are being explored.
MM302 is an HER2-targeting nanoparticle combined with doxorubicin, a
chemotherapeutic agent particularly active in HER2-positive breast cancer.
Unfortunately, HERMIONE trial, comparing MM302 plus trastuzumab versus
physician’s choice plus trastuzumab in HER2-positive breast cancer progressed after
pertuzumab, was recently closed due to unfavourable futility analysis (Hurvitz et al.,
2017) (Table 3).
3.3 Inhibitors of tyrosine kinase
Tyrosine kinase inhibitors (TKIs) were studied in breast cancer to overcome trastuzumab
issues. Being smaller molecules than antibodies, they should be able to cross brain-blood
barrier for treating of cerebral metastasis. They can be administered orally improving
compliance to therapy and reducing hospitalization. TKIs also induce less cardiac adverse
effects than trastuzumab, thus they can be employed in heart-suffering patients.
Moreover, TKIs show a broader specificity than trastuzumab, targeting for example
HER2 isoforms lacking ECD o trastuzumab binding site (Hurvitz et al. 2017).
Lapatinib was the first TKI to be introduced in the clinical practice. It reversibly binds
tyrosine kinase domain of HER1 and HER2. Direct comparison of lapatinib to
trastuzumab and taxane in first-line setting did not show any superiority of lapatinib
neither in survival nor in the safety profile of the drug. On the contrary, in the adjuvant
setting this inhibitor showed benefit in combination with chemotherapy or with
chemotherapy and trastuzumab in terms of progression-free and/or overall survival. An
action on brain metastasis was not clearly shown in specifically designed trials
CEREBREL and EMILIA. Following these results and emergence of newer and more
effective agents such as T-DM1, lapatinib use is now limited to advanced breast cancer as
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a second and further-line of treatment (Loibl and Gianni, 2017; Hurvitz et al., 2017;
Baselga et al., 2017).
Neratinib is an irreversible pan-HER2 inhibitor targeting tyrosine kinase domain of
HER1, HER2 and HER4. Initial studies in vitro demonstrated specificity and superiority
to lapatinib in HER2-positive cell lines. Its action was shown to be mediated by a
reduction in pHER2, pAkt and pErk in treated cell lines. Combination of trastuzumab and
neratinib further inhibited growth of HER2-positive human cell lines in vitro, impeding
reactivation of pHER3 as a compensatory mechanism. In vivo, volumes and weight of
tumours induced by HER2-positive human cell line BT474 were diminished by treatment
with neratinib alone or in combination with trastuzumab. Its action was again mediated by
down-regulation of HER2, pHER2, pHER3, pAkt and pErk which, although not
statistically significant, was even stronger in mice treated with the combination of
neratinib and trastuzumab (Canonici et al., 2013). Clinical efficacy of neratinib has been
evaluated in first- and second-line and on brain metastasis. In the NefERT-T trial,
Neratinib combined with paclitaxel did not show any superiority with respect to
trastuzumab+paclitaxel in early metastatic breast cancer; however, the tyrosine kinase
inhibitor significantly delayed and reduced incidence of brain recurrences. In ExteNet
trial neratinib ameliorated 2-year progression free survival of 2.3% with respect to
placebo in women with grade I-III HER2-positive breast cancer who had completed 1-
year adjuvant trastuzumab (Baselga et al., 2017; Unni et al., 2018). This result granted its
approval in advanced breast cancer by FDA (Food and Drug Administration) in 2017.
EMA (European Medicines Agency) was in turn more cautious and initially refused
permit for neratinib commercialization in Europe; the small improvement in progression
free survival was judged not to outweigh the increased frequency of adverse effects
observed in the neratinib treated arm. Grade 3/4 adverse effects of diarrhoea were indeed
often observed in both trials and prophylaxis with loperamide was requested to prevent
these adverse effects. After re-examination of results, EMA granted neratinib approval
(2018) only in a subset of patients with ER+/PR+/HER2+ disease (triple positive), where
neratinib appeared to elicit a more significant protective effect. Neratinib efficacy is
currently being assessed with respect to lapatinib, both in combination with capecitabine,
in metastatic breast cancer previously treated with two HER2-targeted agents.
Novel tyrosine kinase agents are currently in the pipe-line of clinical development, such
as ONT-380 with an expected improved activity against brain metastasis, tucatinib which
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selectively inhibits HER2 and not HER1 thus reducing adverse effects such as diarrhoea
and skin rush, poziotinib and pyrotinib which show promising activity on tumours
harbouring HER2 mutations. All of them are being evaluated in phase II trials (Escrìvia-
de-Romani et al., 2018) (Table 3).
3.4 Other strategies
Most of HER2 targeted treatments involve antibodies, thus it can be expected that
checkpoint inhibitors could positively modulate activity of the immune system
potentiating trastuzumab action. Thus, various combinations of checkpoint inhibitors,
such as atelimizumab and pembrolizumab, with current standard of care are being
investigated in HER2-positive breast cancer.
Abundant preclinical evidence has demonstrated a role of cyclin D1 and E and cdk4/6 in
HER2-positive breast cancer. Hence, cdk4/6 inhibitors such as palbociclib, ribociclib and
abemaciclib are being evaluated both in neoadjuvant and adjuvant setting (Table 3).
Lastly, barely 40% of HER2-positive breast cancer harbour mutations in PI3K pathway
which may lead to resistance to HER2 targeted therapies; so, it is not surprising that many
inhibitors of PI3K are being developed for use as single agents or in combination with
HER2 targeted therapies. Among them, buparlisib, pilaralisib and copanlisib, apelisib and
tapelisib are being evaluated in phase I or II clinical trials (Escrìvia-de-Romani et al.,
2018) (Table 3).
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Table 2. Pharmacological characteristics of approved anti-HER2 agents.
The table sums up principal pharmacological characteristic of currently approved targeted drugs against HER2. (Modified from Garret & Arteaga, 2011; Loibl & Gianni,
2017).
Trastuzumab Lapatinib T-DM1 Pertuzumab Neratinib
Class Monoclonal antibody Tyrosine kinase inhibitor Antibody-drug conjugate Monoclonal antibody Tyrosine kinase inhibitor
Mechanism of
action
Recombinant humanized
monoclonal antibody that
inhibits ligand-independent
HER2 and HER3
signaling,
inhibits the shedding
from the extracellular
domain, and might trigger
antibody-dependent
cellular cytotoxicity
Dual tyrosine kinase
inhibitor of HER2
Monoclonal antibody
directed at the dimerization
domain of HER2
Antibody–drug conjugate
in
which trastuzumab is
stably
linked to a potent
microtubule inhibitor that
is a derivative of
maytansine
Tyrosine kinase inhibitor
of HER1, HER2, and
HER4
Route of
administration
and half-life
Endovenous, weeks Oral, 24 hours Endovenous, ≈ 4 days Endovenous, weeks Oral, 24 hours
Adverse effects Rare cardiotoxicity and
diarrhea
Rare cardiotoxicity; skin
rush; dose-limiting toxicity
causing diarrhea
No cardiotoxicity; rare
diarrhea
Rare cardiotoxicity;
dose-limiting toxicity
causing diarrhea
No cardiotoxicity; dose-
limiting toxicity causing
diarrhea
Indication HER2-positive early breast
cancer; HER2-positive
metastatic breast cancer
HER2-positive metastatic
breast cancer in
combination with
capecitabine, trastuzumab,
or an aromatase inhibitor
HER2-positive metastatic
breast cancer that has not
already been treated with
chemotherapy medicines,
or treated together with
trastuzumab and docetaxel
for non-operable HER2-
positive breast cancer
HER2-positive advanced or
metastatic breast cancer in
adults who previously
received trastuzumab and a
taxane
In development for the
treatment of HER2-positive
early breast cancer and
metastatic breast cancer
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Agent Mechanism of
action
Reported results Further Development
NOVEL ANTI-HER2 ANTIBODIES
Margetuximab
(MGAH22)
Optimized Fc
domain for
enhanced binding
To the activating
low-affinity Fc
receptor, Fcγ
RIIIA
Phase I monotherapy clinical trial,
12% pts. with PR; PFS of 5.5 months
Phase III trial
(NCT02492711)
margetuximab +
chemotherapy
vs. trastuzumab+
chemotherapy
MCLA-128 IgG1
bispecificfic
antibody with
enhanced ADCC
activity targeting
both HER2 and
HER3 receptors
Phase I/II monotherapy clinical trial
70% CBR.
Further exploration of
MCLA-128 based
combinations with
chemotherapy or
trastuzumab is planned
ZW-25 Bispecific
antibody directed
against two
distinct epitopes
of HER2
Phase I preliminary results: 8 BC pts:
2 PR, 2 SD, 3 PD.
Phase I (NCT02892123)
ANTIBODY-DRUG CONJUGATES (ADC)
SYD 985 Trastuzumab
with an alkylant
prodrug DUBA
(Duocarmicin
derivate) payload
Phase I monotherapy ORR 34% in
HER2-positive and HER2 low breast
cancer
Phase III trial (TULIP)
with a 2:1 randomization
of SYD 985 vs physician
treatment's choice
(NCT03262935)
DS- 8201 HER2 antibody
attached to a
topoisomerase I
inhibitor (DXd)
payload
Phase I ORR 40.2%, DCR
(disease control rate) 91.8%
Phase II trial in patients
resistant or refractory to
T-DM1 (NCT03248492)
TYROSINE KINASE INHIBITORS (TKIS)
Tucatinib ATP competitive,
selectively
inhibits HER2
relative to EGF
Phase Ib:
Capecitabine+Trastuzumab+
Tucatinib: RR 61%; CBR 74%
Capecitabine+
Trastuzumab
± Tucatinib/placebo
Poziotinib Irreversible pan-
HER kinase
inhibitor
Phase II monotherapy: PFS of 4.04
months: DCR of 75.49%.
Phase II trial
monotherapy: HER2-
positive (NCT02659514)
Phase II trial
monotherapy: HER2 or
EGFR mutation or
activated AR or EGFR
pathway (NCT02544997)
Pyrotinib Irreversible TKI
pan-HER kinase
inhibitor
Phase I: RR 50%, CBR 61%,
PFS 35.4 weeks.
Phase III Trial
(NCT02973737):
Pyrotinib+ Capecitabine
vs. Placebo+ Capecitabine
CHECKPOINT INHIBITORS
Atezolizumab Anti-PD-
L1
antibody
NR Phase II KATE2 (NCT02924883): T-DM1+
Atezolizumab/Placebo
Phase 2 single arm (NCT03125928): Paclitaxel+
Trastuzumab
+ Pertuzumab+Atezolizumab
Pembrolizumab anti-PD-
L1
NR Phase Ib (NCT03032107): Pembolizumab+T-
DM1
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antibody
CDK4/6 INHIBITORS
Palbociclib CDK4/6
inhibitor
NR Phase II PATRICIA (NCT02448420):
Palbocilib+ trastuzumab±Letrozol.
Phase III PATINA (NCT02947685):
Palbociclib+Trastuzumab±Pertuzumab
Abemaciclib CDK4/6
inhibitor
NR Phase II trial MonarcHER (NCT02675231):
Abemaciclib+Trastuzumab±Fulvestrant
vs.
Chemotherapy+Trastuzumab
Ribociclib CDK4/6
inhibitor
NR Phase Ib/II trial (NCT02675231):
Ribociclib+Trastuzumab or T-DM1
PI3K INHIBITORS
Alpelisib α-
specific
PI3K
inhibitor
Phase I: Alpelisib+
T-DM1: All pts. PFS
6 months, PFS in 6 pts
with prior T-DM1 10.6
months.
Phase I trial (NCT02167854).
Alpelisib+Trastuzumab for pretreated pts.
requiring a PI3K mutation
Copanlisib Pan-
class
PI3K
inhibitor
NR Phase Ib/II Panther trial (NCT02705859):
Copanlisib+Trastuzumab
Taselisib β-
sparring
PI3K
inhibitor
Phase Ib
(NCT02390427):
Arm A: Taselisib+ T-
DM1:
4% CR, 29% PR, 50%
SD.
Phase Ib (NCT02390427): Arm A: Taselisib+T-
DM1;
Arm B: Taselisib+T-DM1+Pertuzumab;
Arm C: Taselisib+Pertuzumab+Trastuzumab;
Arm D:
Taselisib+Pertuzumab+Trastuzumab+Placlitaxel
Table 3. Novel anti-HER2 agents and combinations
The table reports new anti-HER2 agents by mechanism of action, reported clinical results and further
development. Abbreviations: pts. patients; PR. Partial response; PFS. Progression free survival; vs. versus;
ADCC Antibody-dependent cell-mediated cytotoxicity; CBR. Clinical benefit rate; ORR. Overall response
rate; NR. Not reported; DCR. Disease control rate (Modified from Escriva-de-Romani et al., 2018).
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4. Tumour as heterogeneous society
4.1 The concept of oncogene-addiction and intra-tumour heterogeneity
HER2 expression is not always homogenous and wide-spread in every cell in a tumour.
Clinically, 10% of cells overexpressing HER2 at membrane level or a HER2: CEP ratio
≥2 or a HER2 copy number >6 are enough to classify a breast cancer as HER2-positive
(Loibl & Gianni, 2017). As a consequence, different HER2-positive tumours do not show
the same level of HER2 expression and the same percentage of cells overexpressing
HER2. In 1-40% of HER2-positive breast cancers, indeed, different clones can be
identified with different HER2 expression. These phenomena are known as inter-tumour
and intra-tumour heterogeneity. Moreover, they represent a clinical issue and
heterogeneous tumours for HER2 expression show a shorter overall survival when
compared to homogeneous tumours (Ng et al., 2015).
Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this
complexity, their growth and survival can often be impaired by the inactivation of a
single oncogene. This phenomenon, called “oncogene addiction,” provides a rationale for
molecular targeted therapy (Weinstein & Joe, 2008). It is of main importance for the
success of HER2 targeted therapies to ensure that the vast majority of tumour cells are
indeed addicted to HER2 expression for the maintenance of malignant phenotype
(Escrìvia-de-Romani et al., 2018). In some cases, HER2 could represent a passenger
mutation found in a minority of cells rather than the driver mutation of the tumour
sustaining its proliferation. When HER2 is therapeutically targeted, if the tumour is
addicted to HER2 expression for maintenance of malignant phenotype, cells will undergo
apoptosis, senescence or at least will stop growing. On the contrary, if the tumour is not
addicted to HER2, targeted therapies will not eradicate the disease and may select clones
which show no HER2 overexpression.
4.2 Receptor discordance and loss of HER2 expression
Expression of ER, PR and HER2 has for a long time been considered an intrinsic property
of breast cancer. Nevertheless, receptor discordance between primary tumour and loco-
regional or distant metastases is non-rarely observed and affects not only HER2, but ER
and PR.
ER was found differently expressed in primary tumours and metastasis in percentages
ranging from 7.3% to 51.2% of analysed patients, with metastasis acquiring expression of
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this receptor in 21.5% of and losing it in 22.5% of cases. Alterations in expression of PR
were detected in meta-analytic pooled percentage of 30.9%. Expression of this receptor
was more frequently lost (49.4%) than acquired (15.9%) in the metastasis (Schrjiver et
al., 2018). HER2 discordance percentage between primary tumours and metastasis was
reported between 0% and 34%, with a pooled meta-analysis percentage of 10.8%. HER2
changed twice as often from positive to negative (21.3%) than vice versa (9.5%)
(Schrjiver et al., 2018) (Picture 4).
The role of adjuvant therapy with endocrine inhibitors or trastuzumab is currently under
investigation and literature reports contrasting data. Endocrine therapy is reported to
trigger conversion to ER negative disease in brain metastasis, whereas trastuzumab does
not promote HER2 loss in the same setting (Timmer et al., 2017). In a different study,
trastuzumab in turn appears to increase the rate of loss of HER2 in metastasis (19.8%)
with respect to patients treated with chemotherapy only (9.4%) (Wang et al., 2017).
Effect of receptor conversion on prognosis is controversial, as well. BRITS and
DESTINY clinical trials did not show significant effects of receptor conversion on
patients’ survival (Amir et al., 2012), whereas other studies reported a decreased time to
progression and survival in patients losing HER2 expression in metastasis (Niikura et al.,
2012; Dieci et al., 2013; Wang et al., 2017).
Receptor conversion is a recognized clinical issue and entails a risk of treatment failure in
discordant metastasis. Up-to-date guidelines therefore recommend new assessment of
receptor in any metastasis or recurrences. If a receptor is gained, targeted therapy already
exists and can be promptly administered. On the contrary, when either HER2 or ER
expression is lost, tumours lose their oncogene-addiction and depend on a different
pathway for maintenance of their malignant phenotype. Extensive research is ongoing to
identify oncogenic drivers and therapeutic targets in tumours losing HER2 and ER
expression. Clinical data are not mature yet, to determine whether therapeutic changes
upon receptor conversion actually improve patients’ prognosis (Schrjiver et al., 2018).
Importantly, loss of HER2 expression has been detected in HER2-positive gastric and
gastroesophageal cancer, as well (Pietrantonio et al., 2016).
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Picture 4. Meta-analysis of
HER2 discordance
The tables report discordance
percentages for HER2 of single
studies and the pooled estimate
discordance in primary breast
tumors and paired distant
metastases. Discordance
percentages are shown for total
conversion (A), conversion
from positive to negative (B),
and conversion from negative to
positive (C). Error bars indicate
confidence intervals.
Heterogeneity was assessed
using I2 and Cochran’s Q. CI ¼
confidence interval; df ¼
degrees of freedom (Schjiver et
al., 2018).
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4.3 Breast Cancer Stem Cells and Plasticity
Cancer stem cell concept supports a hierarchical organization of the tumour cells and
predicts that only a specific sub-population with stem cell-like properties, such as the
capacity to self-renew and generate the heterogeneous lineages of cancer cells, is able to
initiate tumorigenesis (Duru et al., 2013). These cells were firstly identified in breast
cancer as a sub-population (1-5%) able to give rise to colonies in vitro and to tumours,
even if extremely diluted, in vivo (Al-Haji et al., 2003). These multipotent cells are
characterized by plasticity, an altered balance between self-renewal and differentiation,
and an active program of EMT, which allow them to sustain tumour growth at different
levels: support of primary tumour, relapse, metastasis and resistance to chemo- and
radiotherapy (Nigam et al., 2012; Kotiyal and Battarchaya, 2014).
At molecular level, breast cancer stem cells (BCSC) are identified by cytofluorimetric
analysis as CD44+/CD24-/low/Lin-; other markers which help characterizing BSCS are
Cd49f, CD29, Sca-1, ESA/EpCAM, cytokeratins 5 and 14, ALDH enzymes, IL1a, IL-6,
IL-8, and urokinase plasminogen activator (UPA) (Al-Haji et al., 2003; Nigam et al.,
2012; Duru et al., 2013). Active pathways sustaining BCSCs are TGF-β, NOTCH,
SonicHedgog, NFkb, Dach-1, p21, cyclin D1 and MAPK/ERK (Velasco-Velasquez et al.,
2013).
EMT is a physiological process essential during embryogenesis, tissue repair and fibrosis.
During metastasis of carcinomas, epithelial cancer cells are believed to undergo EMT in
order to acquire migratory abilities, necessary for metastasis. EMT reprogramming occurs
at transcriptional level and leads to loss of cell polarity and cell-cell adherent junctions,
and gain of mesenchymal stem cells properties with ability to migrate. Master regulators
of EMT are Snail, Slug, Zinc finger E-box-binding homeobox-1 (ZEB1), ZEB2, Forkhead
box protein 1 (FOXC1), FOXC2, Transcription factor 3 (TCF3) and homeobox protein
Goosecoid (GSC). Down-stream pathways activated during EMT are represented by a
network of several stemness signalling pathways such as TGF-β, Wnt/β-catenin, Notch,
JAK/STAT, Hedgehog, inflammatory pathways such as NF-κB, extracellular and
intracellular growth factors such as Epidermal growth factors (EGFs), Insulin-like growth
factor 1 (IGF1), Fibroblast growth factors (FGFs), Platelet-derived growth factor (PDGF)
and interleukins (IL6 and IL8), cell adhesion transmembrane proteins such as E- and N-
cadherins and filament protein vimentin. Altogether, these processes reprogram epithelial
cells to transit to the mesenchymal phenotype (Nami and Wang, 2017).
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BSCSs display a mesenchymal phenotype and localize at tumour expanding periphery.
Although BCSCs are generally negative for both luminal marker and HER2, the latter has
been proposed as a novel regulator of BCSCs. Indeed, it has been found to increase
staminal properties of BCSCs and anti-HER2 targeted therapies have in turn been
associated to a decrease in staminal properties of tumours. An active and supportive role
of HER2 has been reported in all signalling pathways sustaining stemness, such as TGF-
β/Smad, Notch, Wnt/β-catenin and JAK/STAT (Picture 5). However, HER2 appears to
promote EMT as well through structure disruption of the tight junction which leads to
loss of cell poarity; during this process, metalloproteases result up-regulated and cleave
HER2 itself besides many proteins involved in cell-cell and cell-ECM adhesion. Cleavage
of HER2 produces p95HER2 fragment, which lacking the ECD is not recognized by
trastuzumab, but retains signalling activity, leading to resistance (Nami and Wang, 2017).
Picture 5. Cross-talk between HER2 and BCSC signalling pathways
The cartoon describes interaction between HER2 and pathways sustaining cancer stem cells in
breast cancer (Nami & Wang, 2017).
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5. Preclinical models of breast cancer
5.1 Murine models of HER2/neu driven mammary carcinogenesis
Most of our knowledge of the role of HER2 in mammary carcinogenesis is derived from
preclinical models.
Initially, a mutation of neu, the HER2 homolog in rat, was identified in a chemically
induced model of breast cancer and later validated as able to transform NHI 3T3 murine
fibroblast cell line. Mutated oncogene, neuT, harbours a point mutation (V664E) which
triggers dimerization and signalling of neu receptor. Hence, the first preclinical models of
neu driven mammary carcinogenesis were represented by mice transgenic for neuT under
control of MMTV (mouse mammary tumour virus), which restrains expression of the
transgene to mammary epithelium. These mice develop mammary tumours with low
latency and high incidence. Transgenic mice harbouring the proto- oncogene neu still
develop mammary tumours with high incidence, but much longer latency due to time
required for accumulation of tumorigenic mutations (Guy et al., 1992; Muller et al., 1988;
Bose et al., 2013). Different promoters have been used up-stream neu and neuT
transgenes with different phenotypes (Boggio et al., 2000; Andrecheck et al., 2000;
Weinstein et al., 2000; Freudenberg et al., 2009;)
In human tumours, HER2 is not often mutated but amplified and hence overexpressed in
the vast majority of HER2 enriched breast cancers; consequences of this difference have
already been discussed in paragraph 2.3 of this introduction. To better mimic human
carcinogenesis and to yield model for the study of anti-human HER2 targeted therapies, a
murine model has been developed harbouring multiple copies of human HER2 wild-type
gene under MMTV promoter: HER2 is thus overexpressed preferentially in mammary
epithelium. FISH and PCR analysis have revealed 30-50 copies on the transgene inserted
in chromosome 6. HER2 overexpression is tumorigenic in 76% of female mice with a
mean latency of 28.2 weeks (Finkle et al, 2004; De Giovanni et al., 2014).
Histopathological analysis of tumours evidenced solid, papillary and tubular growth
accompanied by high mitotic index and aberrant cellular shape. HER2 expression at
membrane level is high, yet heterogeneous. Spontaneous lung metastasis is found in 23%
of mice (Finkle et al, 2004; De Giovanni et al., 2014).
Full-length HER2 oncoprotein and splice variant Δ16 are co-expressed in human breast
cancer. Therefore, transgenic mice harboring Δ16 have been developed and crossed with
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animals transgenic for the full-length HER2, obtaining F1 mice harboring both isoforms
(Castiglioni et al., 2006; Marchini et al., 2011; Castagnoli et al., 2017; Palladini et al.,
2017).
5.2 Mammary patient derived xenograft models (PDX)
With respect to basic and translational research, breast cancer inter- and intra-tumoral
heterogeneity present significant challenges to generation and use of relevant pre-clinical
models that represent the full spectrum of breast disease (Dobrolecki et al., 2017).
Patient-derived xenografts (PDXs) are an extremely useful tool in the perspective.
Available human breast cancer cell lines and cell lines derived from preclinical models of
mammary carcinogenesis are representative of a limited subset of breast tumors.
Moreover, not all of them are tumorigenic in vivo. PDXs recapitulate and stably maintain
over time the characteristics of originating tumor at genomic, phenotypic, histological,
molecular and metabolic level. A collection of mammary PDXs could hence be
representative of a wider variety of human breast cancers.
Mammary tumors graft in immunocompromised mice with very high rates (≈40%), but
only 10% of implanted tumors actually give rise to a stable PDX, i.e. transplantable for at
least three passages in vivo, with a bias towards more aggressive tumors being more
represented into PDX collections (Dobrolecki et al., 2017).
Recently, a consortium of academic institutions has gathered 537 PDX models,
representative of 500 individual specimen. Implanted samples derived from primary
tumors (79%), pleural effusions (6%), ascites (3%) or metastasis (15%). The vast
majority of PDX in this collection originated from triple negative tumors (56%). Despite
representing 10-15% of all mammary carcinomas, this subtype shows a very high take.
36% of PDXs represent patients with ER+ disease, which is under-represented with
respect to clinical occurrence, since low malignancy of luminal tumors makes it difficult
to obtain PDX of this subtype. Only the remaining 8% represent HER2-positive breast
cancers, due to low take rate and stable PDX yields from this subtype (Dobrolecki et al.,
2017).
PDX are an always renewable resource of tumor tissue, which is useful for in depth and
repeated analysis and for in parallel or subsequent testing of different drugs (Dobrolecki
et al., 2017). Indeed, the US National Cancer Institute (NCI) has replaced their NCI-60
cell line resource (a panel of 60 mammary cell lines used for drug screening) with PDX
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samples, highlighting the importance and acceptance of this resource (Holen et al., 2017).
However, when using PDXs for testing drugs it should be kept in mind that the bias
towards aggressive tumors may falsely infer therapeutic benefit (or indeed not).
Moreover, study of the tumor microenvironment is compromised due to intrinsic species
differences and the lack of immune cells in tolerant hosts (Holen et al., 2017).
It is still under scientific debate, whether PDXs recapitulate metastatic pattern of tumors
of origin. The latter are indeed obtained at the time of surgery and long observation time
may be requested to understand whether PDX metastasize at the same organs of
derivative tumors in patients. However, metastasis in PDX are often observed in lymph
nodes and lungs, whereas breast tumors preferentially disseminate to bone and brain
(Holen et al., 2017).
Initially, the possibility was conceived to exploit PDX models as mouse ‘avatars’ for
personalizing treatment to individual patients. However, clinical decision-making is quick
(weeks), compared with the time taken to establish a PDX (even a year) and low take
rates and high costs further limit use of PDX models as avatar. Hence, currently the
potential of these models is limited to cohort-based preclinical studies (Holen et al.,
2017).
5.3 Models of HER2 loss
Various strategies have been employed to transiently knock-down HER2 expression in
vitro and in vivo, at different stages of tumour development.
HER2 silencing with siRNA, ribozymes on antisense RNA resulted in inhibiting tumour
cell growth both in vitro and in vivo. Cell lines used appear hence to be oncogene-
addicted to HER2, since the stop growing once HER2 expression in down-modulated. In
MMTV-neuT mice, where transgene expression was inducible by tetracycline or
doxycycline, once neuT expression was knockdown, tumours regressed as well (Moasser
et al., 2007).
Sometimes, though, emergence of HER2-neu negative or mesenchymal populations out
of HER2-neu positive or polygonal mammary cell lines has been reported either
spontaneously or in concomitance with drug-resistance.
Cell lines derived from p185(neu)-positive tumours arisen in FVB-NeuN mice (N202)
bearing the rat neu protooncogene driven by the mouse mammary tumour virus
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promoter/enhancer gave rise to p185(neu)-positive and p185(neu)-negative clones. In
vitro, analysis of anchorage-independent growth in soft agar revealed colony formation
from p185(neu)-positive but not p185(neu)-negative cells. Upon in vivo injection,
p185(neu)-positive cells gave rise to fast-growing tumours with a short latency, while
p185(neu)-negative cells required a very long latency time, and the resulting tumours
were invariably p185(neu)-positive (Nanni et al., 2000).
TUBO-P2J is a variant of TUBO cell line. TUBO derive from the tumour of a mice
transgenic for neuT expression (see paragraph 5.1). Cells injected in mice treated with
anti-neu antibody eventually gave rise to lung metastasis, whose cells had lost neu
expression (TUBO-P2J). In this cell line, loss of neu expression was associated with
mesenchymal morphology, resistance to chemotherapy, increased migration and
metastasis and characteristics of EMT, such as loss of epithelial markers and acquisition
of mesenchymal markers both at transcript and at protein level (Song et al., 2014).
SkBr3 and BT474 were kept long-term in increasing concentrations of lapatinib or
AZD8931 (a different tyrosine kinase inhibitor) giving rise to resistant cells lines, which
displayed a decreased expression and phosphorylation of HER2 and HER3. Drug-
resistant cell lines acquired an EMT profile, increased proliferation and migration ability
(Creedon et al., 2016).
Materials and Methods
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1. Mice
The experiments reported in this thesis were performed in three different murine strains:
 Breeders for the two immunodeficient strains, NOD-SCID-Il2rg−/− (NSG) and
BALB/c Rag2−/−Il2rg−/− were received from Jackson Laboratories (USA) and Drs
T. Nomura and M. Ito (Central Institute for Experimental Animals, CIEA,
Kawasaki, Japan), respectively. Animals were inbred at our animal facility and
kept under sterile conditions.
 FVB MMTV.f.huHER2 mice (Finkle et al., 2004) were received from Genentech
Inc. (South San Francisco, CA, USA). In our animal facility human HER2 was
maintained in heterozygosis by crossing male transgenic mice with non-transgenic
FVB female mice purchased from Charles River (Calco, Italy). Mice were
routinely genotyped by PCR analysis (Finke et al., 2004). In this thesis, these mice
will be further referred to as FVBhuHER2.
All experiments were approved by the institutional review board of the University of
Bologna, authorized by the Italian Ministry of Health and performed according to Italian
and European legislation and guide-lines.
2. Cell lines
Cell lines derived from mammary tumors spontaneously arisen in FVBhuHER2 mice and
all their derivatives were previously obtained and characterized in the Laboratory of
Biology and Immunology of Metastasis. Cells were cultured in DMEM (Dulbecco’s
Modified Eagles’ Medium; Life Technologies, Milan) supplemented with penicillin 100
U/ml and streptomycin 100 µg/ml (Life Technologies, Milan), 20% Fetal Calf Serum
(FCS, Life Technologies, Milan) and growth factors, such as Bovine Pituitary Extract (30
µg/ml, BD Biosciences, USA) and MITO Serum Extender (0.5% v/v, BD Biosciences,
USA). Mammary murine cell lines TS/A, obtained at Laboratory of Biology and
Immunology of Metastasis, and its derivative overexpressing mIL-6, TS/A IL-6 (Di Carlo
et al., 1997), were cultured in DMEM supplemented with antibiotics 10% FCS only;
TS/A IL-6 was kept under selection by geneticin 500 µg/ml.
Human mammary cell lines, BT474, MDA-MB 453, SkBr3, MCF7, kindly given to the
Laboratory of Biology and Immunology of Metastasis by Dr. Serenella M. Pupa (Istituto
Nazionale dei Tumori, Milan, Italy), MDA-MB 231 and HCC1954, purchased by ATCC,
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were cultured in RPMI (Roswell Park Memorial Institute; Life Technologies, Milan)
supplemented with antibiotics and 10% FCS only.
Cells were cultured at 37°C in humidified atmosphere at 5% CO2. Cell were split once or
twice a week according to density using trypsin-0.05% EDTA (Life Technologies, Milan)
for detachment. Whenever needed, cells were counted on Neubauer’s hemocytometer
using the vital colorant erythrosine (Sigma, Milan) and harvested for cytofluorimetric or
molecular analysis.
2.1 Long term colture with trastuzumab
HER2stable, HER2labile and HER2loss cells were kept in colture with trastuzumab 30 μg/ml
for two months.
HER2stable and HER2loss cells were harvested twice a week and seeded in medium with or
without trastuzumab. After 28 days, HER2 as well as expression of staminal marker
(CD24 and CD44) was assessed by citofluorimetric analysis and samples were collected
for molecular analysis. Afterwards trastuzumab was either maintained in medium (TRNT
cell lines) or removed (TRT cell lines) for 28 days. Again, HER2 as well as expression of
staminal marker (CD24 and CD44) was assessed by citofluorimetric analysis. At this
time-point samples for RNASequencing were collected as well.
HER2labile cells followed the same protocol with the exception of being splitted once a
week. Every time cells were counted and seeded at a concentration of either 1.6x105
cells/cm2 or 4x104 cells/cm2. Citofluorimetric analysis was performed weekly.
2.2 Sensitivity to demethylating agent
HER2labile and HER2loss cells were seeded at 8x104 cells/cm2. 24 hours after seeding, cells
where treated with vehicle (DMSO 0.02%), 5’ aza-2-deoxycytidine (Sigma) 0.5 µM or 5
µM. Treatment was renewed after 72 hours of treatment. Cells were harvested after 48, 72
and 144 hours of treatment and counted. HER2 expression was determined by
cytofluorimetric analysis.
2.3 Sensitivity to sunitinib in vitro
Sensitivity to sunitinib in vitro was determined under different conditions of culture.
For the experiment under 2D adherent conditions HER2loss cells were plated at 3.125x103
cells/cm2 in 96-well plates (Corning Life Sciences, USA) in medium. After 24 hours from
seeding, cells were treated with Sunitinib 0.1, 0.5, 1, 5 and 10 µM (LC Laboratories, MA,
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USA), or DMSO 0.2% (Sigma) or fresh medium. Each treatment was evaluated in
triplicate. After 72 hours of treatment, WST-1 reagent (Sigma) was added to each well
and absorbance at 450/620 nm was measured 60 minutes thereafter with an ELISA
microreader (Tecan Systems).
For the experiment under 3D non-adherent conditions, HER2loss cells (0.5x103 cells/cm2)
were suspended in a solution of agarose 0.33% (Sea Plaque Agarose; Cambrex
Bioscience Rockland, ME, USA) in medium containing DMSO 0.02% (Sigma) or
sunitinib 1 or 5 µM (LC Laboratories, MA, USA) or no drug. On 24-well plates (Corning
Life Sciences, USA), this overlayer was stratified on a jellified underlayer of 0.5%
agarose in medium containing DMSO 0.02% (Sigma) or sunitinib 1 or 5 µM (LC
Laboratories, MA, USA) or no drug. Colonies were counted after 14-22 days.
Evaluation of long-term sensitivity to sunitinib was performed seeding HER2loss cells
(8x104 cells/cm2) in medium containing sunitinib 5 µM (LC Laboratories, MA, USA) or
DMSO 0.05% (Sigma). Cells were split after 4 days; some samples and supernates were
collected for further molecular analysis. Cells were cultured further on and split according
to density in medium containing sunitinib, DMSO or no drug.
2.4 Tube Formation Assay
HER2loss cells were seeded 8x104 cells/cm2. After 24 hours, medium was replaced with
fresh medium containing either sunitinib 5 µM (LC Laboratories, MA, USA) or DMSO
0.05% (Sigma). After 24 hours of treatment cells were harvested and seeded dropwise
6.3x104 cell/cm2 in 24-well plate (Corning Life Sciences, USA), on a base of Matrigel
diluted 10 mg/ml in DMEM basal medium (Corning, NY, USA) and let solidify 1 hour at
4°C. Plates were incubated at 37°C, 5% CO2 over-night and the formation of vessel-like
channels was observed 16-18 hours after seeding.
2.5 mIL-6 production
Cells were seeded 8x104 cells/cm2 in medium containing either sunitinib 5 µM (LC
Laboratories, MA, USA) or DMSO 0.05% (Sigma) or trastuzumab 30 µg/ml or no drug.
After 4 days, supernates were collected, measured, centrifuged (2000 RCF, 20 min, 4°C)
and filtered through 45 µm filters (Millipore) to eliminate cell debris. Aliquots were
frozen and kept at -20°C.
49
mIL-6 production was analyzed with Mouse IL-6 Quantikine ELISA Kit (R&D Systems)
according to manufacturer’s protocol. Briefly, supernates were diluted in assay buffer and
distributed on wells pre-coated with a specific anti-mouse IL-6 antibody. After 2 hours’
incubation at room temperature, wells were washed three times with wash buffer and
incubated again for two hours at room temperature with an enzyme-linked anti-mouse IL-
6 antibody. After 3 washes, wells were incubated with the enzymatic substrate for 30 min
at room temperature. Absorbance 450/620 nm was read on an ELISA microplate reader
(Tecan Systems). Concentration of each sample was calculated interpolating values on a
standard curve.
3. Murine mammary cell lines xenografts
HER2labile and HER2loss cells were subcutaneously (s.c.) injected in FVBhuHER2 or
Balb/c Rag2-/- Il2rg-/- virgin female mice in the right posterior leg. Cells were diluted in
0.2 ml PBS (Phosphate Buffered Saline). Mice were palped and tumors measured with a
caliper at least once a week. Tumor volumes were calculated as √ × , where a
represents tumor’s major diameter and b tumor diameter perpendicular to a. At necropsy,
tumors were harvested and disaggregated with trypsin-0.05% EDTA for cytofluorimetric
analysis.
3.1 Treatment with trastuzumab in vivo
106 HER2labile cells were subcutaneously (s.c.) injected in FVBhuHER2 virgin female
mice and treated intraperitoneally (ip.) with saline or trastuzumab 4 mg/kg twice a week
starting from day 3 after cell injection. At necropsy, tumors were harvested and
disaggregated with trypsin-0.05% EDTA for cytofluorimetric analysis.
3.2 Treatment with sunitinib in vivo
FVBhuHER2 mice harboring tumors induced by HER2labile or HER2loss cells were treated
with sunitinib 60 mg/kg (LC Laboratories, MA, USA) per os by gavage. Animals in the
vehicle group received METOCELL 0.5%+TWEEN80 0.4% (Sigma).
106 HER2labile cells were subcutaneously injected in the posterior leg of FVBhuHER2
mice treated starting 3 days after cell injection. Treatment in this group was originally
planned on daily basis, but had to be discontinued due to weigh loss in treated mice;
treatment was then continued every second day.
50
105 HER2loss cells were subcutaneously injected in the posterior leg of FVBhuHER2 mice
treated daily (7/7) starting the day after cell injection.
4. Patient Derived Xenografts (PDX)
Tumor fragments of BBR-4, SBR-45 or SBR-18, with a diameter of 3-4 mm, were
serially implanted in the fourth left mammary intact fat pad, in anaesthetized 5-10-week-
old NOD-SCID-Il2rg−/− (NSG) or BALB/c Rag2−/−Il2rg−/− female mice. Mice were
inspected weekly for tumor growth. Tumor volume was measured as previously
described. At necropsy, tumors were harvested for molecular analysis, disaggregated with
trypsin-0.05% EDTA for cytofluorimetric analysis or fixed in 10% buffered formalin
solution (Sigma-Aldrich) for histological and immunohistochemical analysis.
For detection of metastatic dissemination, lungs, brain and femoral bone marrow were
collected in cold phosphate buffered saline (PBS) and dissociated, both mechanically and
with trypsin-0.05% EDTA, obtaining single cell suspensions. Defined fractions were used
to obtain cellular pellets of each organ for quantitative comparison. Ovaries were frozen
directly in vials, in liquid nitrogen, for nucleic acids extraction. In some cases, half of the
lung and brain, one ovary, one femoral bone and the liver were fixed in 10% neutral
buffered formalin solution for histological examination.
For experimental metastasis, BBR-4 PDX tumors of progressed and non-progressed sub-
lines were dissociated to single cell suspensions and counted. 106 viable cells were diluted
in 0.4 ml PBS and injected in a caudal lateral vein of female virgin immunodeficient
mice.
4.1 Histological and immunohistochemical analysis
Histological and immunohistochemical analysis were conducted by pathologists at
Bellaria or Sant’Orsola Hospital; we report the protocol for completeness. Primary or
xenografted human neoplastic tissues were fixed in 10% buffered formalin (Sigma) for
12-24 hours at room temperature and afterwards processed using the
Formalin/Ethanol/Isopropanol/Paraffin protocol by a hybrid tissue processor (Logos,
Milestone Srl, Sorisole IT) to obtain paraffin blocks. Serial sections of Formalin-Fixed,
Paraffin-Embedded (FFPE) tissue were cut, collected on adhesive glass slides (Tom-11,
Matsunami Glass Ind., Ltd Osaka Japan) and air dried for at least 30 min at room
temperature. Immunostaining was performed on FFPE sections in an automated
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Benchmark Ultra Autostainer (Ventana Medical Systems, Inc., Tucson, Arizona, USA)
with the following primary antibodies: anti-Bcl-2 (clone SP66), anti-ER (clone SP1), anti-
PR (clone 1E2), anti-Ki-67 (clone 30-9), anti-HER2 (Pathway clone 4B5), anti-EGFR
(clone EP38Y); anti-p53 (clone DO7). All antibodies were purchased from Ventana,
except anti-EGFR (Thermo Fisher Scientific, Fremont USA or Abcam, Cambridge, UK).
The immunologic reaction was visualized using the Ventana UltraView DAB Detection
kit according to the manufacturer’s instructions. Nuclear immunostaining for ER, PGR,
Ki-67 and p53 was quantified using a semi-automated image analysis system (Image-Pro
plus v.5.0.1, Media Cybernetics Inc., Rockville, USA) on at least 30 randomly selected
200× microscopic fields (2.000 cells) and expressed as percentage of immunostained
neoplastic population. ER and PR were considered positive if >10% of neoplastic
population was immunostained; Ki-67 values were classified as low < 20%, intermediate
20<ki-67<30%, high > 30% of immunostained cells, according to St Gallen consensus
2015 suggestions HER2 expression was evaluated following ASCO/CAP 2013
recommendations. EGFR and Bcl-2 expression were semi-quantitatively evaluated by
examining all the neoplastic population at 100x and classified as negative <10%,
intermediate 10% ≤x<30%, positive >30% of immunostained neoplastic cells.
4.2 FISH analysis
Histological and immunohistochemical analysis were conducted by pathologists at
Bellaria or Sant’Orsola Hospital; we report the protocol for completeness. Dual-color
FISH was employed to analyze HER2 amplification. Standard 4- to 5-μm sections of
FFPE tissues were incubated at 56°C for 2 hours in a dry oven, deparaffinized by washing
(3×15 min) in Bioclear (Natural terpenes-based clearing agent; Bio-Optica, Milan),
dehydrated (2×5 min Dehyol absolute (Bio-Optica) and air dried at room temperature.
After incubation in 2× Saline Sodium Citrate buffer (2× SSC; pH 7.0) at 75°C for 12
minutes, the sections were digested with proteinase K (0.25 mg/mL in 2× SSC; pH 7.0) at
45°C for 12 minutes, rinsed in 2× SSC (pH 7.0) at room temperature for 5 minutes, and
dehydrated using ethanol in increasing concentrations (70%, 85%, and 100%). According
to the manufacturer's instructions, the probe HER-2/CEP17 dual color (KREATECH
Diagnostics, Amsterdam, The Netherlands) was applied on a selected area of
immunohistochemically detectable cells. The hybridization area was covered with a
coverslip and sealed with rubber cement. The slides were incubated at 75°C for 10
minutes for denaturation of both chromosomal and probe DNA and then at 37°C for 20-
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24 hours to allow hybridization. Post-hybridization washes were performed in NP40
0.5%/SSC 2× (pH 7.0- 7.5) at 75°C for 2 minutes and in 2× SSC for 2 minutes at room
temperature. Afterwards, the samples were dehydrated in ethanol as above, and 4′,6′-
diamidino-2-phenylindole 1 μg/ml suspended in anti-fade diluents (KREATECH
Diagnostics, Amsterdam, The Netherlands) was applied for chromatin counterstaining.
FISH analysis was carried out using an Olympus BX61 epifluorescence microscope
(Olympus, Melville, NY).
4.3 Sensitivity to neratinib and tamoxifen
PDX bearing mice at XII and XXII passage in vivo were treated with neratinib (kindly
received from Puma Biotechnology, USA) 40mg/kg, dissolved in methyl-cellulose 0.5%-
tween80 0.4%, 5 times a week per os by gavage. SBR-18 was treated with tamoxifen
(Innovative Research of America, Sarasota, FL, USA) alone or in combination with
neratinib; tamoxifen was administered by subcutaneous implantation of a pellet releasing
0.5 mg of tamoxifen over 60 days. BBR-4 was treated with trastuzumab (Herceptin,
Roche) 4mg/kg, diluted in physiological solution, twice a week, through intraperitoneal
injection (ip.). Treatment began when tumors reached a volume of 0.01 cm3 and were
performed for at least 13-15 weeks or until sacrifice. Control groups did not receive any
treatment.
To evaluate alterations in signal transduction downstream HER receptors, short-term
treatment was performed. In this case, mice bearing PDX tumors of at least 1cm3 were
treated for 4 consecutive days with neratinib (40 mg/kg per os), or 7 consecutive days
with tamoxifen (administered as described above) or tamoxifen and neratinib. 1 hour after
the last treatment with neratinib mice were sacrificed and tumor samples were collected
as described for further molecular analysis.
5. Cytofluorimetric analysis
Harvested cells and tumor samples, previously dissociated as described above to yield
single-cell suspensions, were analyzed by immunofluorescence and cytofluorometric
analysis (CyFlow Space, Sysmex Partec, Germany). Prior to incubation with primary
antibodies, tumor cells were briefly (10 min) incubated with rat anti-mouse CD16-CD32
antibody Fc block (clone 2.4G2; 1:100 dilution; BD, Pharmingen, CA, USA). Primary
antibodies used were mouse anti-human HER2 (MGR2, Alexis Biochemical, Enzo Life
Sciences, Lansen, Swisse) and rat anti-mouse CD140b (PDGRB, APB5, 1:100 dilution;
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Bio-Legend, CA, USA). Anti-mouse IgG AF488 (1:100 dilution; Invitrogen, UK) or anti-
rat IgG (1:40; KPL 02-16-12) were used as secondary antibodies. For direct
immunofluorescence anti-mouse-CD24AF488 (clone M1/69; dilution 1:10; Bio-Legend,
CA, USA) and anti-mouse-CD44PE (clone IM7; dilution 1:10; Bio-Legend, CA, USA)
(Biolegend) were used.
6. Molecular analysis
6.1 Real-Time PCR
DNA was extracted from cellular pellets of murine (8x104 cells/cm2) and human (4x104
cells/cm2) cells harvested 4 days after seeding; 10 ng of DNA per sample were analyzed.
DNA from lung, brain, bone marrow cellular pellets and frozen ovaries of PDX was
extracted over-night at 56°C in an extraction buffer containing 50 mM KCl, 2.5 mM
MgCl2, 0.01% gelatin, 0.45% igepal, 0.45% tween 20 and 120 mg/ml proteinase K in 10
mM Tris-HCl buffer pH 8.3 (all reagents from Sigma, Milan, Italy); proteinase K was
inactivated by 30 min incubation at 95°C. DNA was quantified by Qubit Assay Kit
(Invitrogen) and 1 ng of each sample were analyzed.
RNA was extracted from cellular pellets or frozen tissue sample, which were
mechanically dissociated by gentleMACS Octo Dissociator (Milteny Biotech GmbH,
Bergisch Gladbach, Germany). Extraction was performed according to the TRIzol
protocol (Total RNA Isolation Reagent; Life Technologies, Milan). RNA was quantified
by Qubit Assay Kit (Life Technologies). 1 µg was reverse transcribed with iScript cDNA
Synthesis Kit (Bio-Rad Laboratories, CA, USA). 10 ng of cDNA were analyzed for each
sample.
According to reaction type, DNA or cDNA was amplified using Sso Advanced SyBR
Green Supermix or SsoAdvanced Universal Probes Supermix (Bio-Rad Laboratories, CA,
USA) reagents. Reactions were performed by Thermal Cycler CFX96 (Bio-Rad
Laboratories, CA, USA).
Analysis was performed using Bio-Rad CFX Manager 3.1 Software and relative
quantification was calculated as ΔCt= Ctgene-Cthousekeeping .
HER2 in genomic DNA was amplified with primer qHsaCEP0052301 (Bio-Rad
Laboratories) normalizing over human/mouse PTGER2 (dir
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TACCTGCAGCTGTACGCCAC; rev GCCAGGAGAATGAGGTGGTC; probe
AGAAGCCGCTGCGGA). Copy number of human and murine cell lines was inferred
considering MCF7 and MDA-MB231 to harbor 2 copies of HER2 in the genome.
Disseminated cells in each organ were detected by amplification of a sequence in the α-
satellite region of the human chromosome 17. Primer and probe sequences were derived
from Becker et al., with the sole alteration that the probe carried the non-fluorescent
quencher dye TAMRA at the 39-end (Dir GGGATAATTTCAGCTGACTAAACAG;
Rev AAACGTCCACTTGCAGATTCTAG; Probe
CACGTTTGAAACACTCTTTTTGCAGGATC). To quantify human cells, a standard
curve was constructed by adding scalar amounts of MDA-MB-453 human cells to a
constant quantity of mouse cells. Ct (threshold cycle) of experimental samples were
interpolated in the standard curve and final number of disseminated tumor cells per organ
was obtained considering the fraction analyzed for each organ (Nanni et al., 2012).
HER2 gene-expression in PDX was analyzed using TATA binding protein (TBP) total,
human and mouse genes as housekeeping (Bieche et al., 2014).
Gene expression of HER2, IL-6 and genes linked to EMT profile in FVBhuHER2 cell
lines was quantified considering murine TBP as housekeeping. Primers for this part are
listed in the next page.
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Target gene Primer Conditions
HER2
(Mitra et al.,
2009)
Forward
GTGTGGACCTGGATGACAAGGG
Reverse
GCTCCACCAGCTCCGTTTCCTG
200 nM
Annealing 60°C
Cdh1 qMmuCID0006332
(Bio-Rad Laboratories, USA)
1×
According to
manifacturer
Col3a1 qMmuCID0006332
(Bio-Rad Laboratories, USA)
Col5a2 qMmuCID0011413
(Bio-Rad Laboratories, USA)
Dsp qMmuCID0019458
(Bio-Rad Laboratories, USA)
Fgfbp1 qMmuCID0007813
(Bio-Rad Laboratories, USA)
Igfbp4 qMmuCID0006155
(Bio-Rad Laboratories, USA)
Il1rn qMmuCID0009153
(Bio-Rad Laboratories, USA)
IL6 qMmuCID0005613
(Bio-Rad Laboratories, USA)
Mmp2 qMmuCID00021124
(Bio-Rad Laboratories, USA)
Ocln qMmuCID0005446
(Bio-Rad Laboratories, USA)
Pdgfrb qMmuCID0025167
(Bio-Rad Laboratories, USA)
Sparc qMmuCID0023536
(Bio-Rad Laboratories, USA)
Vcan qMmuCID0005235
(Bio-Rad Laboratories, USA)
mTBP
(Bieche et al.,
2014)
huTBP
(Bieche et al.,
2014)
Forward
CCCTTGTACCCTTCACCAATGAC
Reverse
TCACGGTAGATACAATATTTTGAAGCTG
Forward
AGAACAACAGCCTGCCACCTTAC
Reverse
GGGAGTCATGGCACCCTGAG
200 nM
Annealing 60°C
6.2 HER2 copy number analysis
DNA was extracted from cellular pellets obtained as described in paragraph 6.1 by
PureLinkTM Genomic DNA Mini kit (Life Technologies) according to manufacturer’s
protocol and quantified by Qubit Assay Kit (Life Technologies). HER2 copy number was
quantified by RT-PCR and normalized over human/mouse PTGER2.
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6.3 RNASequencing
Samples detailed in figure 10 were sequenced in collaboration with the equipe of prof.
Calogero. Protocol is reported for the sake of completeness. Pellets were homogenized
and total RNA was isolated by Trizol® reagent (Life Science Technologies, Italy)
following the manufacturer’s specifications. RNAs were quantified using a Nanodrop
ND-100 Spectrophotometer (Nanodrop Technologies, Wilmington, USA) and a 2100
Bioanalyzer (Agilent RNA 6000 Nano Kit, Waldbronn, Germany); RNAs with a 260:280
ratio of ≥1.5 and an RNA integrity number of ≥8 were subjected to deep sequencing.
Sequencing libraries were prepared with the Illumina TruSeq Stranded RNA Library
Prep, version 2, Protocol D, using 500-ng total RNA (Illumina). Qualities of sequencing
libraries were assessed by 2100 Bioanalyzer with a DNA1000 assay. Libraries were
quantified by qPCR using the KAPA Library Quantification kit for Illumina sequencing
platforms (KAPA Biosystems); RNA processing was carried out using Illumina NextSeq.
500 Sequencing. FastQ files were generated via Illumina bcl2fastq2 (Version 2.17.1.14 -
http://support.illumina.com/downloads/bcl2fastq-conversion-software-v217.html) starting
from raw sequencing reads produced by Illumina NextSeq sequencer. Gene and transcript
intensities were computed using STAR/RSEM software52 using Gencode Release 19
(GRCh37.p13) as a reference, using the “stranded” option. Differential expression
analysis for mRNA was performed using R package EBSeq53.
We performed various analyses on differentially expressed genes. Clusterization of genes
according to their molecular function and biological process was performed through
PANTHER web tool (www.pantherdb.org). Protein-protein interactions were investigated
using the STRING database (www.strind-db.org). Gene enrichment analysis was
performed on coding genes. We performed a Gene Ontology (GO) analysis for biological
processes and molecular function and a Kegg pathway analysis (Kyoto Encyclopedia of
Genes and Genomes http://www.genome.ad.jp/kegg) via enrichR web tool
(www.amp.pharm.mssm.edu/Enrichr).
7. Western blot analysis
Proteins were extracted from cellular pellets or frozen tissue samples, which were
mechanically dissociated by gentleMACS Octo Dissociator (Milteny Biotech GmbH,
Bergisch Gladbach, Germany). Extraction was performed in lysis buffer, i.e. PhosphoSafe
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Extraction Reagent (Novagen) supplemented with protease inhibitors (Protease Inhibitor
Cocktail, Sigma 100x). After 10 min incubation, suspensions were centrifuged (12800xg,
15 min, 4°C) and proteins harvested at -80°C for further analysis.
After quantification with DC™ Protein Assay (Bio-Rad Laboratories), proteins were
separated on an 8% polyacrylamide gel and then transferred to polyvinylidene difluoride
membranes (Bio-Rad Laboratories). After blocking in TBST+5% Milk (Bio-Rad
Laboratories), membranes were incubated overnight at 4°C with primary antibodies
detailed in the table below. After 3 washes in TBST, membranes were incubated with
polyclonal horse-radish-peroxidase conjugated anti-rat IgG antibody (1:3000. Bio-Rad
Laboratories) or anti-mouse IgG antibody (sc-2005; 1:1000. Santa Cruz Biotechnology).
Protein presence was detected by chemiluminescent reaction (Bio-Rad Laboratories)
before film exposure. Densitometric analysis was performed using TotalLab software.
Primary
antibody
Clone Dilution Molecular
weight
α-HER2 3B5 1:1000 185 kDa
α-pHER2 Polyclonal 1:1000 185 kDa
α-HER1 D38B1 1:1000 185 kDa
α-pHER1 D7A5 1:1000 185 kDa
α-HER3 D22C5 1:1000 185 kDa
α-pHER3 21D3 1:1000 185 kDa
α-HER4 111B2 1:1000 185 kDa
α-pHER4 21A9 1:1000 185 kDa
α-IGF1R C-20 1:1000 100 and 200 kDa
α-Stat3 124H6 1:1000 86-91 kDa
α-pStat3 D3A7 1:2000 86-91 kDa
α-Akt Polyclonal 1:1000 60 kDa
α-pAkt
(Ser473)
D9E 1:1000 60 kDa
α-MAPK 137F5 1:1000 42-44 kDa
α-pMAPK E10 1:1000 42-44 kDa
α-actin Polyclonal 1:1000 42 kDa
8. Statistical Analysis
Comparisons of growth rate, sensitivity to target drugs, signaling pathways upon
pharmacological treatment were based on Student’s t test. Comparison of survival rates to
1cm3 tumors were based on Mantel-Cox test. Calculation of IC50 (half maximal
Inhibitory Concentration) of sunitinib was based on interpolation of percentages with a
sigmoid dose-response curve. All statistical analyses were performed Prism 5, GraphPad
software, La Jolla, CA, USA).
Results
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1. Overcoming HER2-loss mediated resistance to targeted
therapies
Recently, a murine model of HER2 loss in mammary tumors has been developed and
characterized in the Laboratory of Biology and Immunology of Metastasis directed by
Professor Pier-Luigi Lollini. The model is made up of cell lines, derived from either
spontaneous or induced tumors in transgenic FVBhuHER2 mice, which display a
different dynamic of HER2 expression in vitro and in vivo. HER2stable cell line derives
from a spontaneous mammary tumor and displays a high and stable HER2 expression
(median fluorescence intensity, MFI, 1033 arbitrary units of fluorescence), which is not
lost neither upon in vivo injection nor upon cloning in vitro (i.e. HER2stable AG3 clone
with MFI 875). HER2labile cell line derives from inoculation in vivo of a cell line bimodal
for HER2 expression (26% HER2-negative cells), which was in turn derived from a
spontaneous mammary tumor. HER2labile line displays a high expression of HER2 in vitro
(MFI 558); nevertheless, it gives rise to HER2-negative tumors in vivo as well as HER2-
negative clones in vitro (i.e. L2 clone MFI 4). HER2loss cell line was eventually derived
from a tumor induced in vivo by HER2labile cell line and does not express HER2 neither
on cell surface (MFI 4) nor at intracellular level. Table recapitulates the characteristics of
HER2stable, HER2labile and HER2loss cell lines, which were already reported extensively
elsewhere (Master degree thesis of the candidate, Giusti Veronica, Perdita di HER2 e
sensibilità a terapie mirate nel carcinoma mammario, 2015).
Briefly, HER2stable and HER2labile cell lines grew in vitro as a monolayer of polygonal
cells, whereas HER2loss cell line was constituted by multilayered spindle-like cells.
HER2loss cell line displayed the highest capacity of forming mammospheres in vitro and
its population showed highly staminal characteristics: over 95% of cells were
CD24low/CD44high. All the cell lines were tumorigenic, but HER2loss cells displayed the
shortest latency and time to sacrifice when compared to the other cell lines. Moreover,
when injected intravenously HER2stable and HER2labile cell lines basically did not give rise
to lung metastasis which in turn substituted lung lobes in animals injected with HER2loss
cell line. Lastly, when vascular properties were analyzed in vitro, a tube formation assay
revealed that HER2loss cell line formed more and bigger vascular-like structures in vitro.
In vivo, pericytes were not detectable in the vasculature of tumors arisen upon injection of
HER2labile and HER2loss cell lines, i.e. in HER2-negative tumors.
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To sum up, loss of HER2 expression in HER2loss cell line was accompanied by a spindle-
like morphology, an increased stemness, a greater aggressiveness and superior
vasculogenic activity in vitro; pericytes lack in vasculature of HER2-negative tumors in
vivo.
HER2stable HER2labile HER2loss
Morphology Monolayer of
polygonal cells
Monolayer of
polygonal cells
Multilayered
spindle-like cells
Stemness
(CD24low/CD44high)
3% 1% 96%
Mammospheres
(cells per sphere)
23±1 (806) 17±1
ND
69±9 (5100)
Median latency in vivo
(weeks)
4 3 1
Median time to sacrifice
(weeks)
13 9 3
Experimental metastasis 0-4 0-0 >200
In vitro vascular tube
formation
12 5 115
Presence of pericytes in
vascular structures of
tumors induced by
Yes No No
Table 1. Characteristics of HER2stable, HER2labile and HER2loss cell lines
The table reports morphology of cell lines in adherence; percentage of CD24low/CD44high determined by
FACS analysis; number of mammospheres formed when seeded in ultra-low adherence conditions and
number of cells per mammosphere upon disaggregation; median latency and time to sacrifice upon intra-
mammary inoculation of 106 cells in FVBhuHER2 mice; range of lung metastasis induced by intravenous
injection of 105 cells in FVBhuHER2 mice; number of tubes formed in matrigel 16-18 hours after seeding
(12x103 cells/cm2); presence of pericytes, determined by immunohistochemistry as cells positive for NG-2
expression, surrounding blood vessels in tumors induced by either cell line in vivo. ND= not determinable
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1.1 Trastuzumab promotes HER2-loss in vitro
HER2 loss is a clinical issue and occurs in up to 25% of metastasis (Loibl and Gianni,
2017). Literature reports contrasting data about the role of trastuzumab adjuvant therapy
in promoting HER2 loss in metastasis and recurrences. We set out to understand if and
how trastuzumab could affect loss of HER2 expression in HER2labile cell line. Previous
preliminary experiments (Master degree thesis of the candidate, Giusti Veronica, Perdita
di HER2 e sensibilità a terapie mirate nel carcinoma mammario 2015) had shown that
trastuzumab 10 μg/ml inhibited growth of colonies of HER2labile cell line under non-
adherent 3D culture conditions in vitro: the number of colonies was decreased of 79%
with respect to untreated control. Under adherent 2D culture conditions, trastuzumab had
a much lower, yet still significant, efficacy in inhibiting growth of HER2labile cell line
(<25% inhibition with respect to untreated control). FACS analysis of cells treated for
120 h with trastuzumab 10 μg/ml revealed an increased HER2-negative population in
treated cells (19%) with respect to untreated control (7%).
Hence, we set up a long-term culture with trastuzumab 30 μg/ml for 2 months to verify
whether prolonged treatment with trastuzumab could induce loss of HER2 expression in
HER2labile cell line. HER2labile cells were seeded at high dose (1.6x105 cells/cm2) and low
dose (4x104 cells/cm2). HER2 expression and stemness of treated cells were monitored
over time (fig. 1 and fig. 2).
From day 21 cells at both doses treated with trastuzumab began to acquire some kind of
spindle-like morphology. At day 28 trastuzumab treated low dose seeded cells were
completely spindle-like and maintained this morphology over the next month (fig. 2A and
2D). High dose seeded cells were still mainly polygonal at day 28, but bunches of
spindle-like cells were clearly visible (fig. 1A); afterwards, spindle-like cells took over
and no polygonal cells could be observed with the exception of very little islets
interspersed in the spindle-like multilayer (fig. 1D).
HER2 expression and stemness changed in parallel with morphology. In HER2labile high
and low dose cells treated with trastuzumab, HER2 expression was always almost
completely lost when cells began to acquire a spindle-like morphology (day 28) (fig. 1B
and 2B). HER2labile cells in culture have an extremely limited staminal population (≤ 1%).
In high-dose seeded trastuzumab treated cells, staminal population got gradually
expanded from 35% of cells having lost CD24 expression at day 28 till 65% of cell being
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staminal at day 56 (fig. 1C and 1F). HER2labile cells seeded at low dose and treated with
trastuzumab quickly acquired staminal properties with 46% of cells being staminal at day
28 and 70% at day 56 (fig. 2C and 2F).
Spontaneous changes of morphology, HER2 expression and staminal properties were
observed in untreated populations of cells seeded at low dose, as well. Untreated
HER2labile cells at low dose began to acquire a spindle-like morphology at day 35, hence
slower than trastuzumab treated cells. Change in morphology was accompanied by a
gradual loss of HER2 expression, which was expressed in less than 25% cells at day 56
(fig. 2E), and a gradual increase in staminal population: loss of CD24 expression was
already evidencable in 10% of cells at day 28 (fig. 2C) and staminal population accounted
for 70% at day 56 (fig. 2F). High dose seeded untreated cells remained polygonal in
shape, positive for HER2 expression and staminal population remained limited to 5%
throughout long-term culture (fig. 1D, 1E and 1F).
Of note, removal of trastuzumab from cell culture medium did not restore neither
polygonal morphology, nor HER2 expression, nor CD24high-CD44low population in
HER2labile cells (data not shown).
Altogether, trastuzumab appears to accelerate a spontaneous tendency of HER2labile cells,
when seeded at low dose, to lose HER2 expressionand in parallel acquire a spindle-like
morphology and an increased staminal sub-population.
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Fig. 1. Trastuzumab promotes
HER2 loss in vitro_High dose
HER2labile were seeded at high dose
(1.6x105 cells/cm2) and kept in long-
term culture with normal medium
(untreated; black) or trastuzumab 30
μg/ml (blue).
Photos were shot at Diavert
microscope (250× magnification) at
day 28 (A) and 56 (D).
HER2 expression was quantified by
cytofluorimetric analysis at day 28
(B) and 56 (E). Histogram profiles
show in black cells incubated only
with secondary fluorescent antibody,
in grey profile of untreated cells
incubated with α-huHER2 and in blue
cells treated with trastuzumab
incubated with α-huHER2.
Dot blot of CD24 (x axis) and CD44
(y axis) analyzed by cytofluorimetric
analysis at days 28 (C) and 56 (F).
Dot blots show untreated cells in
black and trastuzumab treated cells in
blue.
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Fig. 2. Trastuzumab
promotes HER2 loss in
vitro_Low dose
HER2labile were seeded at high
dose (4x104 cells/cm2) and
kept in long-term culture with
normal medium (untreated;
black) or trastuzumab 30
μg/ml (green). Photos were
shot at Diavert microscope
(250× magnification) at day
28 (A) and 56 (D). HER2
expression was quantified by
cytofluorimetric analysis at
day 28 (B) and 56 (E).
Histogram profiles show in
black cells incubated only
with secondary fluorescent
antibody, in grey profile of
untreated cells incubated with
α-huHER2 and in green cells
treated with trastuzumab
incubated with α-huHER2.
Dot blots of CD24 (x axis)
and CD44 (y axis) analyzed
by cytofluorimetric analysis at
days 28 (C) and 56 (F). Dot
blots show untreated cells in
black and trastuzumab treated
cells in green.
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1.2 Trastuzumab accelerates growth of HER2-negative tumors in vivo
HER2labile cells give rise to HER2-negative tumors when injected in FVBhuHER2 mice in
vivo. We set out to understand the effect of trastuzumab treatment in such tumors. 106
HER2labile cells were injected subcutaneously (s.c.) in the right posterior leg and mice
were treated with either saline or trastuzumab twice a week starting from day 3 after cell
injection. Animals treated with trastuzumab developed bigger tumors then ones treated
with saline (control); differences in growth rate were statistically significant from day 25
after cell injection. No statistically significant difference was observed in latency between
the two groups (fig. 3). All tumors were HER2-negative both in saline and trastuzumab
treated groups and the vast majority of their populations displayed staminal features
(≥75% CD24 low).
Overall, these data confirm in vitro observations: trastuzumab accelerates growth of
HER2-negative tumors upon in vivo injection of HER2labile cell line, as well.
Figure 3. Effect of trastuzumab in vivo on HER2labile induced tumors
Tumor growth curve of tumors arisen after s.c. injection of 106 HER2labile cells and treated intra-peritoneum
(ip) with saline (black round) or trastuzumab 4 mg/kg (red rectangle) twice a week from day 3 after cell
injection. Each point represents the mean±s.e.m. volume of 4 or 5 mice. Statistical analysis: Student’s t test,
(*) p<0.05.
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2. Unravelling HER2loss
We performed some experiments to understand mechanisms underlying loss of HER2
expression in HER2labile cell line. First of all, we determined whether number of injected
cell or clearance by immune system could influence HER2 expression in vivo.
Furthermore, we evaluated genetic and epigenetic alterations which could impair HER2
expression in HER2loss cell line. Lastly, we performed analysis of transcriptomes and
expression of genes associated to EMT was checked as well.
2.1 Effect of different injection doses
We primarily set out to verify whether and how dose of injected cells could influence
tumor growth and HER2 expression in FVBhuHER2 mice. We injected either 106, or 107
or 2x107 HER2labile cells: the more cells we injected the faster tumors grew (fig. 4A).
Anyway, neither injection dose gave rise to HER2-positive tumors (fig. 4B).
Hence, high injection doses of HER2labile cells do not give rise to HER2-positive tumors,
strengthening the concept that close cell-cell contact is required for HER2labile cells to
maintain HER2 expression.
Figure 4. Different doses of HER2labile in vivo
(A) Tumor growth curve of HER2labile cells injected s.c. in FVBhuHER2 mice at different doses: 106
(round) ,107 (square), 2x107 (triangle). Each point represents the mean±s.e.m. of 2 mice. Statistical analysis:
Student’s t test p<0.05 versus 106 (*) or 107 (#).
(B) Histograms represent expression of huHER2 of one representative tumor for each indicated group;
black profile refers to cells incubated with secondary antibody only, colored profiles indicate cell incubate
with α-huHER2.
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2.2 Is HER2 loss due to immunological selection in vivo?
According to the theory of immune-surveillance, immune system can edit tumors
eliminating highly immunogenic clones. Low immunogenic remaining cell have thus
been selected for accumulating mutations which enable them to escape from immune-
surveillance and are often more aggressive.
HER2loss cell line was obtained from in vivo injection of HER2labile cell line in
FVBhuHER2 mice, i.e. immunocompetent mice tolerant to HER2 expression. Anyway,
immune system could still react against and clear out HER2-positive clones selecting the
more aggressive HER2-negative sub-population in vivo. To verify if this was the case, we
inoculated HER2labile cells in immunocompromised female mice (Balb Rag2-/-; Il2rg-/-).
HER2labile cells were tumorigenic with 100% incidence in immunocompromised mice;
tumors grew even faster than in immunocompetent mice possibly due to absence of
inhibitory effect of immune system (fig. 5A). Nevertheless, all tumors arisen in the
immunocompromised mice were negative for HER2 expression, as well (fig. 5B).
From these results we can conclude that B, T and NK cells are not involved in clearance
of HER2-positive cells from injected HER2labile population.
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Figure 5. HER2labile cells in immune-compromised mice
(A) Tumor growth curve of 105 HER2labile cells injected s.c. in immunocompetent (FVBhuHER2) mice
(solid square) or immunocompromised (Balb rag2-/-; Il2rg -/-) mice (solid round, dotted line). Each point
represents the mean±s.e.m of 3 mice. Statistical analysis: Student’s t test p<0.05 versus 106 or 107.
(B) Histograms represent expression of huHER2 of one representative tumor for each indicated group;
black profile refers to cells incubated with secondary antibody only, blue profiles indicate cell incubate with
α-huHER2.
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2.3 HER2 copy number analysis
We set out to verify whether HER2loss cells had lost the transgene in their DNA. Copy
number analysis was performed on HER2stable, HER2labile and HER2loss cells. We also
included a murine HER2-negative cell line derived from a mammary tumor (TS/A) and
normal tissue from FVB non-transgenic mice as negative controls, normal tissue and
spontaneously arisen tumors from FVBhuHER2 transgenic mice as positive controls and
human mammary tumor cell lines with different known levels of HER2 expression. We
considered MCF7 and MDA-MB-231, reported in literature as HER2-negative, as bearing
2 copies of HER2. Our analysis revealed 22±5 copies of HER2 in normal tissue from
transgenic mice and 32±1 copies in tumors spontaneously arisen in such mice; this
mirrors the 30-50 copies reported in literature (Finkle et al., 2004). HER2stable cell line
bore 51 copies of HER2 transgene and was thus comparable with human mammary
cancer BT474 cell line (61 copies). HER2labile and HER2loss cell lines had 19 and 18
copies of HER2, respectively, being thus comparable to SkBr3 (13 copies) human
mammary cancer cell line (fig. 6).
This result confirmed that HER2loss cells actually harbor HER2 transgene and that its
silencing must be due to other mechanisms at transcriptional or translational level.
Figure 6. HER2 copy number
HER2 copy number was analyzed by RT-PCR on DNA extracted from HER2stable (black solid round),
HER2labile (blue square) and HER2loss (red triangle) cells, negative controls (black empty round), positive
controls (green rhombus), human mammary cell lines known to be HER2-positive (light green rhombus) or
HER2-negative (grey empty round). Each point represents the ΔCt of a sample, calculated as (CtHER2-Cth/m
PTGER2). Copy number was calculated considering MCF-7 and MDA-MB-231 having 2 copies of HER2.
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2.4 Is HER2-loss a matter of epigenetics?
To assess whether loss of HER2 expression was due to a hyper-methylation event
determining its silencing, we treated HER2loss cells with 5’ aza-2-deoxycytidine (0.5 and
5 µM) for six consecutive days. In parallel, we conducted the same experiment on
HER2labile cells to verify if the demethylating agent could induce a switch to
mesenchymal phenotype.
Treatment with 5’ aza-2-deoxycytidine had a cytostatic effect on HER2loss cell line and at
each point we harvested as much cells as we had seeded (2x106 cells; 8x104 cells/cm2)
(fig. 7A). No changes in HER2 expression were registered (fig. 7C).
On HER2labile cell line, treatment with 5’ aza-2-deoxycytidine 0.5 µM was cytostatic,
whereas the higher dose was cytotoxic and cell yield kept decreasing over time (fig. 7B).
No major changes in morphology and HER2 expression were observed in the lower dose
of treatment. With 5’ aza-2-deoxycytidine 5 µM, cells had a much lower HER2
expression (fig. 7D). Sporadically, some spindle-like cells were observed as well.
Thus, demethylation is not able neither to restore HER2 expression in HER2loss cells nor
to induce a complete switch to spindle-like phenotype in HER2labile cells.
Figure 7. Effect of demethylation on HER2loss and HER2labile cells
Cells were seeded at 8x104 cells/cm2 and treated with 5’ aza-2-deoxycytidine 0.5 µM (triangles) or 5 µM
(squares) or medium only (round). Graphs (A) and (C) refer to HER2loss, (B) and (D) to HER2labile cell lines.
(A) and (B) Cell counts at indicated time-points.
(C) and (D) HER2 expression evaluated by flow-cytometry and reported as fluorescence intensity (MFI).
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2.5 Differential gene-expression of EMT genes in models of HER2loss
Previous data from a PCR Array had demonstrated a differential expression of EMT-
linked genes in HER2loss cell line when compared to HER2stable cell line. Up-regulated
genes were Col3a1, Col5a2, Col1a2, Pdgfrb, Igfbp4, Sparc, Versican, Mmp2, Wnt5a,
Itg5a, Nudt3, TCF4, ZEB-1, ZEB-2 and TGF-β1. Down-regulated genes were Cadherin,
Occludin, Keratin 7 and 14, Fgfbp1, Il1rn, Desmoplakin, Desmocollin 2, F11r, Sox10.
Wnt5b, Serpine1, Snai3, Notch1, Mmp9, Erbb3, EGFR, Tmeff and Bmp7. Genes in bold
were validated in RT-PCR and their dynamic of expression was studied in HER2stable,
HER2labile, HER2loss and HER2labile cells treated with trastuzumab (TRT).
Some polymorphisms in Il1rn have been linked to increased risk of breast cancer
(Slattery et al., 2014). In our model Il1rn was found down-regulated in HER2loss cell line,
with respect to HER2stable and HER2labile cell lines. Il1rn was down-regulated in HER2labile
TRT cells, both at day 28 and 56 (fig. 8).
Fgfbp1 (fibroblast growth factor binding protein 1) is up-regulated in various
adenocarcinomas and appears to have a proangiogenic activity (Tassi et al., 2007). In our
model, it resulted down-regulated in HER2loss cells and to a lesser extent in HER2labile
TRT cells at days 28 and 56 (fig. 8).
Cdh1 (E-cadherin 1), Dsp (desmoplakin) and Ocln (occludin) are molecules involved in
different types of cell-cell adherence also known as markers of epithelial cells. Cdh1 is a
transmembrane glycoprotein which connects cells together at adherent junction. A role
for loss of E-cadherin expression causing EMT is often been proposed and its down-
regulation has often been linked to poor prognosis and invasiveness (Velasco-Velasquez e
al., 2013; Freundenberg et al., 2008; Ashaie et al., 2016; Prieto-Garcìa et al., 2017; Wong
et al., 2018). Accordingly, in our model Cdh1 is down-regulated in HER2loss cells and to
lesser extent in HER2labile cells treated with trastuzumab. Dsp is involved in cell adhesion
at desmoplaques. Loss of its expression has been linked to invasiveness and progression
in cancer (Pang et al., 2004). We observed a great inhibition of Dsp in HER2loss cells and
to a lesser extent in HER2labile TRT cells, which is in accordance with highly tumorigenic
and metastatic properties of HER2loss cell line. Ocln is still involved in cell adhesion and
particularly in regulation of cell membrane permeability at tight junctions. Ocln has been
found down-regulated in HMLE (human primary epithelial breast cells immortalized
through expression of T cell antigen SV40) cells transduced with Snail (a known driver of
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EMT) or knocked-out for Cdh1 expression (Guen et al., 2017). Accordingly, Ocln was
found down-regulated both in HER2loss and HER2labile TRT cells (fig. 8).
Col3a1 and Col5a2 encode two different chains of fibrillary proto-collagen, an
extracellular-matrix (ECM) component, which is abundant in extensible mesenchymal
tissues. Col3a1 has been found up-regulated in TFG-β1 induced EMT in renal and lung
carcinoma cell lines (Hosper et al., 2013). A down-regulation of Col5a2 has been in turn
reported in pig fibroblasts facing mesenchymal-to-epithelial transition (MET), the
opposite process to EMT (Shi et al., 2013). Accordingly, in our model both Col3a1 and
Col5a2 are up-regulated in HER2loss cell line with respect to HER2stable cell line.
HER2labile cells displayed an intermediate expression of collagen, which was up-regulated
in HER2labile TRT cells to levels even higher than HER2loss cell line (fig. 8).
Igfbp4 (insulin like growth factor binding protein 4) sequesters and down-modulates
activity of IGF in blood and exerts therefore an inhibitory effect on cell growth.
Nevertheless, it has been reported as up-regulated in glioblastoma U434 cell line, where it
promotes EMT, invasiveness and is correlated to down-regulation of Cdh1 (Praaven et
al., 2014). Our model mirrors U434 as Igbp4 is up-regulated in HER2loss cell line with
respect to HER2stable. Again, HER2labile expresses Igfbp4 at intermediate level and its
expression is up-regulated after treatment with trastuzumab (fig. 8).
Vcan, Sparc and Mmp2 are ECM molecules with a known role in proliferation,
migration and angiogenesis. Their up-regulation is a common event in several carcinomas
other than breast cancer and is often linked to EMT and poor prognosis. Vcan encodes the
chondroitin-sulfate proteoglycan versican, whose down-regulation in MCF10A,
stimulated by Snail, dampens their migratory properties (Zhang et al., 2017). Vcan is up-
regulated in HER2loss cells with respect to HER2stable; HER2labile, though minor variatons
among samples, displays an intermediate expression which is augmented after
trastuzumab treatment. Sparc (secreted protein acidic and rich in cysteine) has been
shown as able to induce EMT together with an immunosuppressive microenvironment in
murine breast cancer cell lines (Sangaletti et al., 2016). It results expressed at good levels
in all the cell lines, with HER2labile and HER2loss cells expressing it slightly more than
HER2stable cell line. In HER2labile TRT cells, Sparc expression was slightly enhanced.
Mmp2 is a metalloproteinase whose expression has been reported down-regulated in a
model where EMT was inhibited silencing STEAP1 (Xie et al., 2018). Its expression was
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maximal in HER2loss cells, followed by HER2labile and eventually HER2stable cell line and
was up-regulated in HER2labile TRT with respect to untreated cells (fig. 8).
Pdgfrb (platelet derived growth factor β) encodes the receptor for a growth factor which
stimulates proliferation of mesenchymal cells. It has been reported,together with PDGR-
α, as a down-stream target of Twist and Zeb1 and Foxq1 (fork-head box Q1),
transcription factors inducing EMT (Meng et al., 2015). In our model it is up-regulated in
HER2loss cells and HER2labile TRT cells, whereas it is overall down-regulated in the other
cell lines, though minor variatons among samples occur in HER2labile cells (fig. 8).
To sum up, Ilrn, Fgfbp1, Ocln, Dsp, Cdh1 are all down-regulated in HER2loss and to a
lesser extent in HER2labile TRT cells. For these genes, HER2labile cell expression
resembles HER2stable cell line. Col3a1, Col5a2, Igbp4, Sparc, Vcan, Mmp2 and Pdgfrb
were in turn up-regulated in HER2loss and HER2labile TRT cells at similar levels.
HER2labile basal expression of these genes was intermediate between HER2stable and
HER2loss. Of note, trastuzumab removal after switch to spindle-like morphology did not
alter expression of above reported genes. Hence, trastuzumab removal was not able to
restore basal expression of these genes, back to level of untreated HER2labile cells (data
not shown).
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3. RNASequencing
Final aim of this study was not only to unravel mechanisms underlying HER2 loss, but
also and primarily to identify new therapeutic targets in HER2-positive breast cancers
having lost HER2 expression.
In collaboration with Prof. Federica Cavallo, Raffaele Calogero and Maddalena Arrigoni
and Martina Olivero (Università di Torino), the transcriptomes of different cell lines were
compared to highlight differences in gene expression and possibly identify therapeutic
targets in HER2 loss. HER2stable, HER2stable AG3, HER2labile, HER2labile TRT, HER2labile
TRNT and HER2loss cells were used for the analysis (see results paragraph 1 for detailed
description of these cell lines). Moreover, HER2stable and HER2loss cell lines were treated
with trastuzumab 30 µg/ml long-term for 30 days, as well as HER2labile; afterwards,
trastuzumab was removed (TRNT lines) or maintained for further 30 days (TRT lines).
HER2labile cell line lost HER2 expression in these conditions, as showed in paragraph 1.1
(fig. 1 and fig. 2). HER2stable and HER2loss cell lines did not undergo any changes in
morphology, HER2 expression and stemness (fig. 9). Inclusion of HER2stable TR(N)T
cells and HER2loss TR(N)T cells permit us on the one hand to identify genes not linked to
lability of HER2 expression and on the other hand to identify those whose expression is
modified upon trastuzumab binding to HER2. Figure 10 reports all cell lines included in
this analysis and their derivation.
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Figure 9. Long-term trastuzumab in HER2stable, HER2labile and HER2loss cells
HER2stable (A) HER2labile (B) and HER2loss (C) were kept in culture with trastuzumab 30 µg/ml for 30 days;
afterwards, cells were treated for further 30 days (TRT cells) or trastuzumab was removed (TRNT cells).
Histograms show HER2 expression by cytofluorimetric analysis with black profile referring to cells
incubated with secondary fluorescinated antibody only and red profile to cells incubated with α-huHER2.
Dot blots report CD24 and CD44 expression, examined by cytofluorimetric analysis.
A
B
C
NT TRNT TRT
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Figure 10. Cell lines included in RNASequencing
The figure illustrates cell lines whose transcriptomes were analyzed and their derivation. All cell lines in green are HER2-positive, show epithelial morphology and a
reduced staminal population. All cell lines in red have no HER2 expression, spindle-like morphology and an increased staminal population.
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3.1 HER2labile versus HER2loss
First of all, we compared transcriptomes of HER2labile and HER2loss cell lines. Stunningly,
only 8 genes were differentially expressed between the two cell lines: 7 genes were down-
regulated and only 1 was up-regulated in HER2loss cell line. Down-regulated genes were
represented by Myh14, Wnt7b, Cdkn2b, Krt8, Ifitm 10, Postn and Krt7; Pla2g7 was in
turn the only gene up-regulated in HER2loss.
The low number of genes detected by this comparison is maybe due to the low number of
samples included in the analysis (3 replicates of HER2labile vs 3 replicates of HER2loss).
The paucity of detected genes in turn did not permit any further clustering and analysis of
pathway and we only performed a bibliographical research to understand how these genes
and their products could be linked to phenotypic differences between HER2labile and
HER2loss cell lines.
Mhy14 encodes a non-muscular myosin which has been found expressed in human
mammary cell lines derived from luminal carcinomas, but not from basal-like
carcinomas. EMT induction with TGF-β in murine cell line NMuMG reduces expression
of the myosin (Beach et al., 2011). Moreover, Mhy14 has been found down-regulated in a
model of progression of tongue carcinoma; clinical data indicate a correlation between its
low expression and lethality (Perez-Valentia et al., 2018). Accordingly, in our model
Myh14 is down-regulated in HER2loss and correlates well with its aggressive and
mesenchymal phenotype.
Cdkn2b encodes the inhibitor of cell cycle p15, which induces arrest of the cycle in G1/S
binding and sequestering Cdk6, needed for subsequent cycle steps. This tumor-suppressor
gene has been found hyper-methylated and hence down-regulated in breast cancer (Buyru
et al., 2009) and in particular in the triple-negative subtype (Ansems et al., 2014). In our
model, its down-regulation in HER2loss cell line is in accordance with its decreased
doubling time with respect to HER2labile cell line.
Cytokeratin are biological marker of a luminal or at least epithelial commitment. Krt7
and Krt8 encode K7 and K8, respectively, which have been found expressed in 94% of a
breast cancer cohort and associated to a better prognosis (El-Rehim et al., 2004). In
particular, K8 is associated to low invasiveness in human mammary cell lines and in turn
its absence correlates with a migratory and undifferentiated phenotype (Iyer et al., 2013).
79
As expected, due to their morphology, HER2loss cells have lost expression of K7 and K8
with respect to HER2labile cell line. This difference mirrors differences in migratory
phenotype and metastatic potential between HER2labile and HER2loss cell lines.
Ifitm10 is a member of INF-induced membrane protein family, which is involved in
proliferation and cell-cell adhesion. Recently, a read-through involving ifitm10 and
CTSD (cathepsin D) was identified specifically in mammary carcinomas. Its inhibition in
human mammary MCF7 cell line hampers cell proliferation (Varley et al., 2014). In our
model, Ifitm10 is down-regulated in HER2loss cell line: this could be interpreted as an
important gene for HER2labile cells proliferation, whereas HER2loss cells may rely on
different pathways.
Wnt7b encodes a soluble signaling factor belonging to Wnt family, which was originally
uncovered as preferential integration site of mouse mammary tumor virus (MMTV), thus
indicating a strong link to mammary tumors. It has been found up-regulated in human
mammary triple-negative cell lines MDA-MB231 and BT-20 and in 10% of human
mammary carcinomas (Huguet et al., 1994). It cooperates with TGF-B pathway in
maintenance of a mesenchymal and migratory phenotype in mammary carcinoma cells
(Sundqvist et al., 2018). Surprisingly, in our model this gene is down-regulated in
HER2loss cell line.
Postn encodes periostin, an ECM protein with anti-apoptotic, pro-angiogenic, pro-
metastatic and genetic instability promoting activities which favor mammary carcinoma
(Ruan et al., 2009). In triple negative tumors it appears involved in maintenance of
staminal niche (Lambert et al., 2016). Unexpectedly, this gene was down-regulated in
HER2loss cell.
Pla2g7 is a phospholipase with a known pro-metastatic role in MDA-MB-435 and BT549
human mammary cell lines, where it also promotes EMT. It is abundantly expressed in
triple negative, where it is also associated to worst prognosis (Lehtinen et al., 2017).
Pla2g7 is the only up-regulated gene in HER2loss and its activities well copes with its
aggressiveness and mesenchymal phenotype.
To some up, differential expression of Myh14, Cdkn2b, Krt7 and Krt8 and Pla2g7 well
mirrors differences in phenotype between HER2labile and HER2loss cell lines. In turn, we
would expect Wnt7b, Postn an Ifitm10 as up-regulated in HER2loss, due to their
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association with aggressiveness and stemness. Their up-regulation in HER2labile could
represent a spy of these cells being prone to acquisition of mesenchymal characteristics or
relying on different pathways for maintenance of malignant phenotype.
3.2 HER2-positive versus HER2-negative
All HER2-positive cell lines in our model (in green in figure 10) were compared to all
cell lines which have lost HER2 expression (in red in figure 10). This analysis identified
751 differentially expressed genes; 409 of them were up-regulated in HER2-negative cell
lines and 349 were down-regulated.
The gene lists were first of all analyzed through PANTHER to obtain a functional
classification of transcripts. Genes down-regulated in HER2-negative cells, thus up-
regulated in HER2-positive cells, 109 (45%) had a binding and 78 (31%) a catalytic
molecular function. Most genes clustered in metabolic (114; 20%) and cellular processes
(157;27%), this last cluster gathering together genes principally involved in cell
communication (55; 67%). Other highly represented biological process (>50 genes
clustered) were response to stimuli (60; 10%), biological regulation (62; 18%) and
developmental processes (54; 16%). Most genes involved in developmental processes
were subcategorized in cellular development (15; 29%) (fig. 11A). Among the 409 genes
up-regulated in cell lines which have lost HER2 expression, 111 (39%) had a binding and
112 (39%) a catalytic molecular function. Most genes clustered in metabolic (137; 35%)
and cellular processes (179;45%), this last cluster gathering together genes principally
involved in cell communication (55; 31%). Highly represented biological process (>50
genes clustered) were response to stimuli (50; 13%) and biological regulation (51; 13%)
Many genes involved in response to stimuli clustered again in response to toxic
substances (20; 40%) (fig. 11B).
A second analysis, through STRING, was focused on interaction between gene products
of gene down- and up-regulated in HER2-negative cell lines with respect to HER2-
positive cells (fig. 12A and fig. 13A).
329 genes out of 349 up-regulated in HER2-positive cell lines were mutually interacting
in a network (Protein Protein Interaction enrichment value p<01 e-16). Some new knots
emerged, such as CDH1, Stat3, Erbb2, Notch1, Kit, SPTAN1, PTPN1, STAT5A and B,
JUP, ITGB3, FGFR1, PAK1, Cul1, IL5 and EFNB1 (fig. 13A). ErbB2 resulted down-
regulated in HER2loss cells. Indeed, many of these knots of interaction are directly linked
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to HER2 iper-expression and have been reported as up-regulated in HER2-positive
human breast cancers. For example, Stat signaling is widely reported in all breast cancer
subtypes and particularly Stat3 is associated to HER2-positive breast cancer (Furth P.,
2014). PTPN1 and PAK1 are involved in HER2 signaling at different levels. Cul1 is
involved in HER2 mediated oncogenesis, since this ubiquitin-ligase leads to p27
degradation, which is increased in HER2-positive tumors (Zhang et al., 2004). IL5 and
EFNB1 have been reported as up-regulated specifically in HER2-positive or enriched
breast cancer (Koenig et al., 2016; Fernandez-Nogueira et al., 2016), whereas FGFR1
can be found co-amplified with HER2 in breast cancer and the co-amplification can be
considered a poor prognosis indicator (Chen et al., 2018). Hence, up-regulation of
PTPN1, FGFR1, PAK1, Cul1, IL5 and EFNB1, and their interactor could be expected in
HER2-positive samples.
Other genes up-regulated in HER2-positive cells account for their polygonal shape and
growth in a monolayer of closely interacting cells. Among these, Cdh1 is a known
marker of epithelial cells whose lost is frequently associated with EMT and is therefore
up-regulated in polygonal HER2-positive cell lines (see paragraph 2.5). JUP encodes a
part of the sub-membranous complex of intermediate junctions and desmosomes, is
therefore found mostly in epithelial cells and its high expression is reported to hamper
migration and invasiveness in mammary tumors. Moreover, it has been found associated
to HER2 iper-expression (Silvrikoz et al., 2013). Notch1 is activated by cell-cell contact
and together with Kit is involved in maintenance of cell proliferation and staminal
properties. Moreover, c-KIT expression is epigenetically downregulated during breast
epithelium transformation and cancer development via KIT promoter hypermethylation
(Janostiak et al., 2018). Achieving a mesenchymal phenotype, HER2loss cells loose
mutual contacts and consequently Notch1 expression. Notch1 and Kit may represent key
signaling pathway for proliferation of HER2-positive cell lines, whereas HER2loss cells
loose addiction from these factors.
Lastly, some up-regulated genes were correlated to luminal cell differentiation. For
example, SPTAN1 encodes a fodrin involved in movement and secretion. High level of
these proteins and their interactors in HER2-positive cell lines can hence indicate their
luminal differentiation, which is lost in HER2 loss.
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Unexpectedly, ITGB3 was found up-regulated in HER2-positive cells. In contrast, in
literature this integrin is reported as up-regulated in stressful conditions such as hypoxia
and appears to promote a migratory and invasive phenotype activating EMT through
Snail and TGF-β (Sesè et al., 2017). It was also found up-regulated in triple negative
mammary carcinomas and related to its migratory properties (Klahan et al., 2014). ITGB3
over-expression in HER2-positive cells seems in contrast with these observations.
Most genes up-regulated in HER2-negative cells were significantly mutually linked in a
network (PPI enrichment value p=1.0e-16), as well; main knots of interaction with more
than 20 interactors were VEGF, MYC, FN1, VIM, PTGS2, PDGFRB, DCN, CAV1,
CDKN1A, ENO2 and many more knots with at least 10 interacting genes were identified
(fig. 12A).
Again, many of these genes are known to be down-regulated in HER2-positive human
breast cancer or have in turn been associated with basal-like breast cancers. FN1 has been
described as down-regulated in HER2 overexpressing carcinomas (Mackay et al., 2003);
hence, in our model, once HER2 expression is lost, FN1 expression is restored. Moreover,
Fn1 and VIM (a known marker of mesenchymal cells) expression, together with
CD44high/CD24low phenotype, have been found strongly associated to apocrine, basal-
like and triple negative breast cancers in a population of Omani women (Lakhtakia et al.,
2017). ENO2, VEGFA and PTGS2 are involved in angiogenesis and directly
transcriptionally regulated by HER2 (Al-Ammedine et al., 2013); their increased
transcription in HER2-negative cell lines must hence be up-regulated by different
mechanisms. It however copes well with increased ability of forming vascular tube in
vitro of HER2-negative cells.
Other genes and their interaction are known for their role in promoting tumor cell
aggressiveness, EMT or sustaining proliferation of mesenchymal cells. This category was
the most interesting to us, because it could reveal which genes and pathway HER2-
negative cells actually rely on for proliferation and maintenance of malignant phenotype.
Dcn and Cav1 encode a proteoglycan and a scaffold protein, respectively, which
normally exert a tumor-suppressive action binding growth factor and mediating their
degradation (Zhang et al., 2018). In our model, Dcn and Cav1 up-regulation could be
responsible of a more intense degradation of HER receptors and may be a spy for HER2-
negative cell lines relying on a different pathway for proliferation. Cdkn1a encodes the
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inhibitor of cell cycle p21; despite being a tumor-suppressor, high levels of cytoplasmic
p21 together with high levels of cyclin B and p53 have been correlated to poor prognosis
in breast cancer, regardless of HER2 expression (Abbas and Dutta, 2009). In our model,
p21 could hence be linked to more aggressive properties of HER2-negative cell lines.
MYC is an oncogene whose expression is markedly high in triple negative with respect to
ER-positive and HER2-positive breast carcinomas (Fallah et al., 2017). In our model, its
iper-expression in lines which have lost HER2 expression reflects their affinity to triple
negative breast cancer cells. Lastly, PDGFR-β is a growth factor receptor which sustains
growth and proliferation of mesenchymal cells; it is hence reliable that this receptor may
sustain growth of HER2-negative cell lines as well. This hypothesis grew stronger
analyzing the list of genes up-regulated in HER2-negative cells with the database
ArchS4-kinase: 50 or more of these genes resulted significantly correlated to the kinase
activation of PDGFR-β and its isoform PDGFR-α.
Through EnrichR, we looked for significant enrichments in biological processes or
pathways. Up-regulated biological processes and pathways in HER2-positive cells
comprising more than 10 genes were represented by positive regulation of protein
modification processes, protein localization at membrane, proteoglycans in cancer and
regulation of actin cytoskeleton (fig. 13B and 13C). Considering processes and pathways
involving less than 10 genes, genes up-regulated in HER2-positive cells were also
significantly associated to processes of cell junction assembly as well as differentiation
and epithelial cell development. HER2-negative cells were instead significantly enriched
for pathways or biological processes of PI3K-Akt signaling, proteoglycans in cancer,
focal adhesion, protein processing in endoplasmic reticulum, lysosome, ECM
organization, positive regulation of migration, angiogenesis, exocytosis, biosynthesis,
PkB signaling, cellular biosynthesis processes and response to oxidative stress (fig. 12B
and 12C).
To sum up, HER2-positive cells show an increased epithelial differentiation and cell-cell
communication. Most knots and processes highlighted in analysis can be related to these
two functions or to HER2 signaling itself. HER2-negative cell lines show indications of a
lost addiction from HER2 signaling, an increased angiogenesis and migration and an
expression profile which often reflects those of triple negative or basal-like breast
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cancers. Myc and PDGFR-B showed up as possible oncogenes sustaining proliferation of
HER2-negative cell lines.
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Figure 11. HER2-negative versus HER2-positive
Functional clustering of genes down-regulated (A) and up-regulated (B) in HER2-negative cells analyzed
through PANTHER database. Upper graphs refer to molecular function, lower graphs to biological process.
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Figure 12. HER2-negative versus HER2-positive
Analysis of genes up-regulated in HER2-negative cells. (A) Graph bar lists gene with more than 10
molecular interactors. (B) Significantly enriched biological Processes and (C) KEGG pathways analyzed
with EnrichR.
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Figure 13. HER2-negative versus HER2-positive
Analysis of genes down-regulated in HER2-negative cells. (A) Graph bar lists gene with more than 10
molecular interactors. Significantly enriched biological Processes (B) e KEGG pathways (C) analyzed with
EnrichR.
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4. Inhibiting HER2loss cells
RNASequencing analysis results indicated PDGFR-B as a possible molecule sustaining
growth of HER2-negative cell lines. We therefore chose it as a target of therapy with
sunitinib. Sunitinib is a small-tyrosine-kinase inhibitor approved by EMA for therapy of
renal cell carcinoma and imatinib-resistant GIST (gastrointestinal stromal tumors).
Sunitinib is a multi-targeted molecule which has been shown to inhibit PDGFRs, VEGFR
and c-Kit. PDGFRs and VEGFA, VEGFR ligand, both resulted up-regulated in HER2loss
cells, so observed effects of this molecule could be due to inhibition of either target. First
of all, we validated PDGFR-B expression at protein level and performed some in vitro
experiments to assess its efficacy and mechanism of action. Lastly, we checked its
efficacy in vivo as well, in tumors induced by HER2loss cells or by HER2labile cells (which
give rise to HER2-negative tumors).
4.1 PDGFR-B validation in HER2lossmodel
PDGFR-B had already been individuated as a differentially expressed molecule in
HER2loss cell line when compared to HER2stable cell line in a previous PCR Array
analyzing genes linked to EMT. Its up-regulation at RNA level has hence already been
validated; PDGFR-B has been found up-regulated in HER2labile cell treated with
trastuzumab as well (see fig. 8). DGFR-B expression at protein level was checked by
flow-cytometry. PDGFR-β was detected only in HER2loss cells, whereas the other cell
lines were completely negative (fig. 14A). Of note, in HER2labile TRT and TRNT which
became spindle-like after treatment with trastuzumab, PDGFR-B expression at protein
level was enhanced as well (fig. 14B).
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Figure 14. Expression of PDGFR-B
Figure shows PDGFR-B expression at protein level determined by FACS analysis. Black profile refers to
cell incubated with secondary fluorescinated antibody only; red profile refers to cell incubated with α-
PDGFR-B.
4.2 Treatment with sunitinib of HER2loss cells in vitro
We determined sunitinib efficacy in inhibiting growth of HER2loss cell line both under
2D-adherent and 3D-non-adherent culture conditions.
Under 2D adherent conditions, HER2loss appeared sensible to sunitinib. Sunitinib 1 µM
already showed poor effects on cell growth, whereas sunitinib 10 µM completely
inhibited growth of HER2loss cell line. IC50 was calculated as 4.66 µM (fig. 15A).
We chose concentrations of 1 and 5 µM for further analysis under 3D-non-adherent
conditions. Untreated cells formed big sprouting colonies (79±4) as well as cells treated
with sunitinib’s vehicle (DMSO 0.05%). Sunitinib 1µM dramatically reduced size of
colonies, but colony count was reduced only of 20%. Sunitinib 5 µM was able to
completely impede growth of any colonies in this setting (fig. 15B and C). Hence,
HER2loss cells resulted sensible to sunitinib in vitro.
In a different experiment, HER2loss cells were seeded 8x104 cell/cm2 and treated with
sunitinib 5 µM (fig. 16A). Untreated cells and vehicle treated cells remained spindle-like
and grew in multilayer. After 4 days of treatment, cells treated with sunitinib 5 µM
acquired mostly a more polygonal shape and cells appeared to grow in a monolayer with
fewer spindle-like cells on a different focus. These cells gradually lost this morphology
and turned back spindle-like, but the same and more pronounced alterations in
morphology were observed treating HER2loss cell line with a higher dose of sunitinib (10
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µM) (fig. 16B). Despite cells acquiring a more polygonal shape, HER2 expression
remained negative as shown by RT-PCR analysis (fig. 16C). In this setting, sunitinib
effect on cell growth appeared reduced with respect to previous experiments, maybe due
to the presence in the medium of extra growth factors such as BPE and MITOSE.
Figure 15. Sunitinib in vitro.
(A) Inhibition curve of HER2loss cell line under 2D-adherent conditions by WST-1 analysis. (B) Bars report
absolute number of colonies grown out of HER2loss cells seeded in soft-agar (3D-non-adherent conditions).
Statistical analysis: Student’s t test, * and # <0.05 versus control or vehicle, respectively. (C) Pictures of
soft-agar colonies of untreated (black outline) and cells treated with sunitinib 1 µM (pink outline) or 5 µM
(orange outline). Photos were shot at Diavert microscope, 2,5× magnification.
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Figure 16. Sunitinib alters morphology of HER2loss cells
HER2loss cells (8x104 cells/cm2) were treated with medium only (untreated) or DMSO 0.05% or sunitinib 5-
10 µM.
(A) Growth curve of untreated (black round) and vehicle cells (blue rectangle) and cells treated with
sunitinib (red triangle).
(B) Analysis of HER2 at mRNA level by RT-PCR analysis, normalized over TBP (total binding
protein) expression (ΔCt=Ctgene-CtTBP).
(C) Photos were shot at Diavert microscope, 250× magnification.
4.3 Modulation of IL-6 following treatment with sunitinib
After 4 days of treatment with sunitinib, surnatants were collected from treated and
untreated cells and IL-6 production was checked. IL-6 is a cytokine involved in
inflammation and angiogenesis; it has been reported to induce EMT which is implicated
in emergence of BCSC. High levels of this cytokine have been linked to poor clinical
outcome in breast cancer patients. Lastly, its up-regulation has been reported in a model
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of BT474/PTEN- treated long-term trastuzumab (LTT), which became spindle-like upon
treatment: here, IL6 appeared to trigger an inflammatory loop which leads towards
acquisition of a staminal, basal-like phenotype and resistance to trastuzumab (Korkaya et
al., 2012). Moreover, HER2loss and HER2labile induced tumors show an abnormal
angiogenesis in vivo, characterized by absence of pericytes, which could be due to an
elevated production of IL-6 (Gopinathan et al., 2015). Due to this experimental
observation and similarities between BT474/PTEN-/LTT and HER2labile TRT cells, we
decided to investigate IL-6 expression and production in our model of HER2 loss and in
response to treatment with sunitinib.
IL-6 has not been found in surnatants of HER2labile cells, where its concentration is
inferior to 30 pg/ml. In turn, HER2stable and HER2loss cells produced IL-6 with mean
concentrations of 316±55 pg/ml and 999±188 pg/ml, respectively. Surprisingly in our
model, IL-6 was not elevated in HER2labile cells treated long-term with trastuzumab
(TRT) and its concentration remained almost undetectable (fig. 17A).
Treatment with sunitinb in HER2loss cells managed to reduce IL-6 production (fig. 17B).
We also checked activation of IL-6 down-stream pathways to IL-6, such as Stat3, by
western blot analysis. We found a down-regulation of pStat3 upon treatment with
sunitinib (fig. 17C).
To sum up, IL-6 production was increased in HER2loss cells with respect to the other cell
lines. It was almost undetectable in HER2labile cells and spindle-like HER2labile TRT did
not start producing this cytokine. Sunitinb was able to decrease its production in HER2loss
treated cells as well as to inhibit down-stream pathway. We can therefore speculate an
involvement of IL-6 in HER2loss spindle-like morphology and basal-like features, which
calls for further investigation.
4.4 Sunitinib modulates angiogenesis in vitro
HER2loss has a greater ability than HER2stable and HER2labile of forming vascular tubes in
vitro. We performed a Matrigel Tube Formation Assay on vehicle treated cells and cells
treated with sunitinib.
After 24h of treatment, cells were seeded in matrigel and tube formation was observed
after 16 hours. Vehicle-treated cells formed spheres sprouting out many tubes each, which
were mutually interconnected. HER2loss cells treated with sunitinib lost their capability of
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forming tubes and cells formed only close-agglomerated spheres with no branches (fig.
17D).
Figure 17. Sunitinib effects on IL-6 and angiogenesis
(A) and (B) Concentration of IL-6 determined by ELISA. Surnatants were collected 4 days after seeding
and eventually treatment of indicated cell lines. Positive control is a murine cell-line transduced with IL-6
(TS/A-IL6).
(C) Western blot analysis of Stat3 and pStat3 in HER2loss cells treated with medium only, DMSO 0.05% or
sunitinib 5 µM for 4 days.
(D) Matrigel Tube Formation Assay of HER2loss cells treated DMSO 0.05% or sunitinib 5 µM treated for 24
hours before seeding in Matrigel. Photos (Diavert microscope, 2,5× magnification) were shot 16 hours after
seeding.
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5. Sunitinib in vivo
Lastly, we checked sunitinib action on HER2-negative tumors induced by inoculation of
HER2labile and HER2loss cell line in FVBhuHER2 mice in vivo.
HER2labile cells grew in vivo after a long latency period. Sunitinib was able to
significantly slow down tumor growth from day 37 and also significantly improved
survival to 1 cm3 tumors with respect to untreated mice (fig. 18A). Importantly, all
tumors in treated as well as vehicle groups were negative for HER2 expression (data not
shown). HER2loss cells, even if injected at lower dose, grew much quicker with tumors
tripling their volumes in just one week. In this setting, sunitinb was not able to impede
tumor growth or improve survival (fig. 18B).
Figure 18. Sunitinib in vivo
(A) 106 HER2labile cells injected in FVBhuHER2 mice treated every second day from +3; (B) 105 HER2loss
cells injected in FVBhuHER2 mice treated daily (7/7) from +1 after cell injection. Animals received
METOCELL 0.5%+TWEEN80 0.4% (vehicle) or sunitinb 60 mg/kg per os. Each point represents the
mean±s.e.m. of 5 mice. Statistical analysis of growth curve: Student’s t test, * p< 0.05.
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6. Neratinib in a mammary patient-derived-xenograft collection
6.1 Establishment of a mammary patient-derived-xenograft collection
Recently, a collection of mammary patient derived xenografts (PDX) was established at
the Laboratory of Biology and Immunology of Metastasis, directed by Professor Lollini,
in collaboration with the equips of Professor Foschini (Bellaria Hospital, Bologna) and
Professor Taffurelli (Sant´Orsola-Malpighi Hospital, Bologna). A total of fresh 66 non-
consecutive primary breast cancer specimens were received shortly after surgery and
immediately implanted orthotopically in the mammary fat pad of immune-deficient mice.
Table 2 describes the clinical features of tumors implanted. Most tumors were invasive
ductal carcinomas (IDC) (59; 89%). Grading was generally high with half of implanted
tumors scoring grade III (33; 50%). On the other hand, tumor sizes were rather small and
little node invasion was noticed; indeed, approximately half samples scored T1 (33, 50%)
and showed no node invasion (29; 44%). Proliferation index was evenly distributed and
varied from low (27; 41%) to high (24; 36%). Most samples were hormone receptor
positive (55; 83%) and only 15 (23%) showed HER2 amplification or overexpression.
Altogether the characteristics of our panel of primary tumors mirrored the proportions
observed in most patient populations in the clinic.
6.2 Stable PDX attainment classified by intrinsic subtypes
According to intrinsic subtypes classification, the majority of implanted specimens
received were luminal A (31; 47%), nevertheless no stable PDX transplantable in vivo for
more than 3 passages was obtained for this subtype even if one tumor actually grafted at
1st passage in vivo. 14 of the implanted tumors were luminal B (21%): 2 stable PDXs
were obtained for this subtype. Triple positive tumors represented 15% of received
samples (10); two specimens actually grafted in mice but no stable PDX was obtained for
this subtype. Despite HER2-positive tumors’ rarity (5; 8%) in implanted tumors, this
subtype showed the highest take (4; 80%) and PDX production (2; 40%). None of the few
triple negative tumors implanted (6; 9%) gave rise to a stable PDX. Table 3 summarizes
rates of engraftment and stable PDX attainment by intrinsic subtype. The final collection
can hence count 2 luminal B, 2 HER2-positive and 1 triple negative PDX. Overall 7.5%
of the implanted tumors produced a stabilized PDX.
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PARAMETER Cases (%)
HISTOLOGY
Invasive ductal carcinoma (IDC) 59 89
Invasive lobular carcinoma (ILC) 6 9
Invasive mucinous carcinoma (IMC) 1 2
GRADE
III 33 50
II 22 33
I 11 17
TUMOR SIZE
T1 33 50
T2 29 44
>T2 2 3
Not evaluated 2 3
NODE INVASION
N0 29 44
N1 17 26
≥N2 15 23
Not evaluated 5 7
HORMON
RECEPTORS
ER+ and/or PR+ 55 83
ER- and PR- 11 17
HER2 EXPRESSION
HER2 overexpression or amplification 15 23
PROLIFERATION
Ki-67 high 27 41
Ki-67 intermediate 15 23
Ki-67 low 24 36
Table 2. Clinical features of primary tumors implanted
The table records the main clinical features of tumors received from surgery, such as histology, grading,
staging (T= size and N=nodular invasion), receptor status (estrogen receptor, ER; progesterone receptor,
PR; and HER2) and proliferation index (Ki-67).
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Luminal A Luminal B HER2 Triple-
positive
Triple-
negative
Implanted tumors 31 (47%) 14 (21%) 5 (8%) 10 (15%) 6 (9%)
Grafted tumors
(1st passage)
1 2 3 2 1
Stable PDX (%)
(3rd passage)
0 (0%) 2 (14%) 2 (40%) 0(0%) 1 (17%)
Table 3. PDX attainment by intrinsic subtype
The table classifies implanted tumors by intrinsic subtype according to ASCO/CAP 2015 suggestions and
records how many specimens grafted (i.e. grown in mice at first passage) and how many gave rise to a
stable PDX (i.e. transplantable to the third passage) in mice.
6.3 HER2 expressing PDXs: features of originating tumors
Among the 5 stable PDX models attained at our laboratory: 2 were luminal B, 2 were
HER2-positive, whereas 1 was triple-negative. We chose the luminal B PDX showing
some evidence of HER2 expression (PDX-SBR18) and the two HER2-positive PDX
(PDX-BBR4 and PDX-SBR45) and for further analysis. The characteristics of tumors
originating these PDXs are detailed in table 4.
The tumor giving rise to PDX-SBR18 was classified as luminal B. It was small and
presented limited node invasion. Its proliferation index was high. The implanted
specimen showed low p53, intermediate Bcl2 and no HER1 expression.
The two tumors clinically classified as HER2-positive, giving rise to PDX-BBR4 and
PDX-SBR45, shared only the receptor status (ER-, PR-, HER2+) and the high
proliferation index. All other immune-histological parameters analyzed differed greatly.
The tumor originating PDX-BBR4 was little and did not show any node invasion,
whereas PDX-SBR45 originated from a bigger tumor with a higher node grade. PDX-
BBR4 originating tumor had a high expression of Bcl2 and p53, but showed no HER1
expression. On the contrary, PDX-SBR45 originating tumor was negative for Bcl2 and
p53 but positive for HER1 expression.
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PDX-SBR18 PDX-BBR4 PDX-SBR45
Intrinsic subtype Luminal B HER2-positive HER2-positive
pT T1c T1c T2
pN N1 N0 (sn -) N2 (+9/25)
Hormone
receptors
ER+ PR- ER- PR- ER- PR-
HER2 score 2+ 2+ (amplified) +3
Ki-67 High High High
Bcl2 Intermediate Positive Negative
P53 6 100 0
HER1 Negative Negative Positive
Table 4. Characteristics of tumors originating HER2 expressing PDX
The table records the major features of tumors originating PDX-SBR18, PDX-BBR4 and PDX-SBR45
detected by hysto-pathological analysis such as intrinsic subtype defined following suggestions of St.
Gallen consensus 2015, pT (size), pN (node invasion), HER2 score according to ASCO/CAP 2013
recommendations, proliferation index (ki-67), expression scores for Bcl-2 (B cell lymphoma 2), p53 (tumor
protein p53) and HER1.
6.4 HER2-expressing PDX: stability of growth parameters and hysto-
pathological features
Growth and hysto-pathological characteristics of HER2-expressing PDX were followed
over time in several passages in vivo to assess their stability.
No dramatic receptor conversion was observed over time in any of the PDX models and
there were no changes in intrinsic subtypes. HER2 score in PDX-SBR18 varied randomly
from score 0/1+ to 2+ over time, whereas PDX-BBR4 and PDX-SBR45 scored 3+ in any
analyzed sample (Table 5).
PDX-SBR18 and PDX-SBR45 remained stably ER+PR- and ER+/PR+, respectively, over
time; in turn, some PR expression was observed in PDX-BBR4 passages V-VII (1%-3%)
(Table 5).
HER1 expression remained negative in PDX-SBR18 and PDX-BBR4 throughout this
observation, whereas some fluctuations occurred in PDX-SBR45 around the intermediate
score (Table 5).
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All tumors retained a high proliferative index over time. Bcl2 and p53 expression was
stable in PDX-BBR4 and PDX-SBR45, whereas in PDX-SBR18 a slight increase in these
parameters was observed over time indicating a possible selection of a more aggressive
subpopulation in vivo (Table 5).
Growth parameters such as latency and growth rate were also followed over time up to
the XII passage in vivo. No significant alterations were observed in PDX-SBR18 latency
or time to 1cm3 after passage II-III (fig. 19A). PDX-BBR4 showed a trend towards
increased growth rate and a significantly decreased survival to 1 cm3 tumors in passage
IV-V and later passages with respect to passages II-III (fig. 19B). PDX-SBR45 showed
an increased growth rate and significantly decreased survival to 1cm3 tumor in late
passages (VI-VII-VIII) compared to II-III and IV-V (fig. 19C).
Overt metastasis was never observed in our PDX collection from I to XII passage.
Presence of disseminated tumor cells (DTCs) was checked in target organs (lung, bone
marrow, brain and ovaries) by RT-PCR. In PDX-SBR18, DTCs were found in the lung of
4 out of 19 animals analyzed (21%); no other human cells were detected in any other
organ. PDX-BBR4 tumor cells disseminated to lung, bone marrow and ovaries in less
than 10% of analyzed animals. PDX-SBR45 rarely disseminated to the same organs. In
both PDX-BBR4 and PDX-SBR45 a maximum of 1500 DTCs per organ was detected
(Table 6).
Overall, histological characteristics were rather stable over serial passages in vivo in our
PDX collection. Increased growth rates over time were observed in PDX-BBR4 and
PDX-SBR45, thus indicating a smooth selection of more aggressive clones. DTCs were a
seldom event in our PDX collection.
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Passage in
mice
Hormone
receptors Ki-67 Bcl2 p53 HER1 HER2
PDX-SBR18
Patient ER+ PR− High Int 6 Neg Sc2+
I ER+ PR− High Int 0.1 Neg Sc0/1+
II (n=2) ER+ PR− High Int 1.1-0.1 Neg Sc2+ 20% - Sc1+
III (n=3) ER+ PR− High Int/Pos 14-19 Neg Sc2+ 70%-Sc1+
IV ER+ PR− High Int 28 Neg Sc1+/2+
V (n=3) ER+ PR− High Int/Pos 13-35 Neg Sc1+/2+-Sc2+80%
VI (n=3) ER+ PR− High Int/Pos 6-26 Neg Sc2+ 15%-Sc1+/2+
VII (n=2) ER+ PR− High Int/Pos 6-21 Neg Sc1+/2+
VIII (n=3) ER+ PR− High-Int Int/Pos 15-21 Neg Sc1+/2+- Sc2+
IX (n=2) ER+ PR− High Int/Pos 10-48 Neg Sc1+/2+
PDX-BBR4
Patient ER− PR− High Pos 100 Neg Sc 2+ (FISH Pos)
II ER− PR− n.d. Pos 98 Neg Sc 3+ (FISH Pos)
III ER− PR− High Pos 100 Neg Sc 3+ (FISH Pos)
IV ER− PR− High Pos 100 Neg Sc 3+ (FISH Pos)
V ER− PR 1% + High Pos 100 Neg Sc 3+ (FISH Pos)
VI ER− PR 3%+ High Pos 100 Neg Sc 3+ (FISH Pos)
VII ER− PR 2% + High Pos 100 Neg Sc 3+ (FISH Pos)
XII ER−PR- High Pos/Int 100 Neg Sc 3+ (FISH Pos)
XV ER−PR- High Pos/Int 100 Neg Sc 3+ (FISH Pos)
PDX-SBR45
Patient ER− PR− High Neg 0 Pos Sc3+
I ER− PR− High Neg 0 Neg Sc3+
II (n=2) ER− PR− High Neg 0 Pos/Int Sc3+
III (n=3) ER− PR− High Neg 0 Neg/Int-Pos Sc3+
IV (n=4) ER− PR− High Neg 0 Neg/Int-Int Sc3+
V ER− PR− High Neg 0 Int Sc3+
VII ER− PR− High Neg 0 Int Sc3+
Table 5. Stability of hysto-pathological features over time in HER2 expressing PDX
The table records hysto-pathlogical features of HER2 expressing PDX in serial passages in vivo. If not else
stated, data refer to one tumour per passage.
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Figure 19. Stability of growth parameters and histological features in HER2 expressing
PDX
The figure shows the growth curve and the percent survival to 1 cm3 tumor over serial passages in vivo of
PDX-SBR18 (A), PDX-BBR4 (B) and PDX-SBR45 (C). Statistical analysis of growth curve: Students’ t
test, (C) II-III versus IV-V (*) and VI-VII-VIII (#) p<0.05 weeks 14-18. Statistical analysis of survival
curve: Mantel-Cox test: (B) II-III versus VI-VII-VIII (§) and IX-X-XI-XII ($) p<0.05; (C) II-III versus IV-
V (*) and VI-VII-VIII (#) p<0.05.
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Table 6. Multiorgan dissemination ability of HER2 expressing PDX
The table records incidence and range of disseminated tumor cells (DTC) detected by RT-PCR evaluating
the α-satellite region of the human chromosome 17 in lung, bone marrow (right+left), brain and ovary
(right+left).
6.5 Neratinib in HER2-positive PDX
Susceptibility to neratinib was evaluated in PDX-BBR4 and PDX-SBR45 in vivo.
Treatment was carried on for 15-17 weeks.
PDX-BBR4 at XII passage in vivo was highly responsive to neratinib and the drug was
able to withhold tumor growth in 100% of treated mice. Neratinib daily treatment (5 days
per week) was withdrawn after 15-17 weeks and its effect appeared to be prolonged over
time. Only one mouse (33%) slowly relapsed and its tumor reached a volume of 1.0 cm3
after 20 weeks from treatment withdrawal. The other mice (66%) remained tumor-free for
more than one year after treatment initiation (65-82 weeks) until sacrifice occurred due to
tumor unrelated causes (fig. 20A and 20B).
In PDX-SBR45, Neratinib was able to halt tumor´s growth throughout treatment duration
(15 weeks) and its effect was prolonged over time. Indeed, after treatment discontinuation
all animals remained tumor-free for at least 15 weeks. 3 out of 5 animals (60%) relapsed
and showed tumors of 1cm3 after at least 9 months (42 weeks) from treatment initiation
(fig. 20D and 20E).
6.6 Signaling alterations induced by neratinib in HER2-positive PDX
Molecular alterations induced by treatment with neratinib were investigated in mice
treated for 4 continuous days starting with 1 cm3 tumors.
Drug administration in PDX-BBR4 led to a reduction in expression of all members of
ErbB family (p<0.05 HER1, HER2 and HER4) and to a significant decrease of all their
phosphorylated forms, thus indicating an induced receptor down-modulation. IHC
analysis reported this PDX to be negative for HER1 expression (i.e. less than 10% of cells
PDX Analysed organs
Lung Bone Marrow Brain Ovaries
Incidence
(%)
DTC
(range)
Incidence DTC
(range)
Incidence DTC
(range)
Incidence DTC
(range)
PDX-SBR18 4/19 (21%) 0-3000 0/20 0-0 0/19 0-0 0/18 0-0
PDX-BBR4 3/33 (9%) 0-1500 2/37(5%) 0-
1000
0/35 0-0 1/36(3%) 0-100
PDX-SBR45 1/13 (8%) 0-1500 1/14(7%) 0-
1000
0/13 0-0 2/14(14%) 0-500
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were positively stained), still some expression was eobserved through western blot
analysis. Of note, reduction in HER3 levels was the most variable between analyzed
mice, hence no statistical significance was reached. Downstream of HER2 receptors there
was a significant reduction in the phosphorylated form of Akt, whereas MAPK signaling
was not hampered by the treatment. Moreover, a trend towards a decreased Stat3
expression was registered in treated mice, but expression of pStat3 was not varied upon
treatment (fig. 20C).
Short term treatment with neratinib in PDX-SBR45 led to a reduction in expression of all
members of ErbB family except for HER4, which was not expressed in this PDX, (p<0.05
for HER1, HER2) and to a significant decrease of all their phosphorylated forms, thus
indicating an induced receptor down-modulation. Of note, reduction in HER3 levels was
the most variable between analyzed mice, hence no statistical significance was reached.
Downstream effectors of this blockade were pAkt and pMAPK, which resulted both
significantly down-modulated. Other alterations following neratinib treatment were
represented by a decreased expression of Stat3, yet pStat3 levels were not diminished by
treatment with neratinib (fig. 20F).
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Figure 20. Neratinib susceptibility and molecular alterations in HER2-positive PDX
PDX-BBR4 was treated with neratinib per os 40mg/kg (red square); control mice are indicated with a black round. The
red dotted lines indicate when the treatment was stopped.
(A) Tumor growth curve of PDX-BBR4 and PDX-SBR45, respectively; (B) Survival rates to 1 cm3 tumors of PDX-
BBR4 and PDX-SBR45, respectively. Statistical analysis of survival curve, Mantel-Cox test, # p< 0.05).
(C) shows a representative image of the western blot analysis of ErbB family members and downstream signaling in
untreated and neratinib group (short-term treatment) of PDX-BBR4 and PDX-SBR45, respectively. The bar graphs
report band intensity normalized over actin for each protein of untreated group (solid black) or neratinib (checked red).
Statistical analysis: Student’s t test, * p<0.05; ** p<0.01, *** p<0.001.
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Figure 20. Neratinib susceptibility and molecular alterations in HER2-positive PDX
PDX-SBR45 was treated with neratinib per os 40mg/kg (red square); control mice are indicated with a black round. The
red dotted lines indicate when the treatment was stopped.
(D) Tumor growth curve of PDX-BBR4 and PDX-SBR45, respectively; (E) Survival rates to 1 cm3 tumors of PDX-
BBR4 and PDX-SBR45, respectively. Statistical analysis of survival curve, Mantel-Cox test, # p< 0.05.
(F) shows a representative image of the western blot analysis of ErbB family members and downstream signaling in
untreated and neratinib group (short-term treatment) of PDX-BBR4 and PDX-SBR45, respectively. The bar graphs
report band intensity normalized over actin for each protein of untreated group (solid black) or neratinib (checked red).
Statistical analysis: Student’s t test, * p<0.05; ** p<0.01, *** p<0.001.
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6.7 Neratinib susceptibility in luminal B PDX
Neratinib action in PDX-SBR18, a luminal B enriched with HER2 expression, was
studied in comparison and concert with tamoxifen, the standard of care for luminal B
tumors regardless of their HER2 status.
Treatment with tamoxifen alone significantly reduced tumor growth starting from week 3
of treatment and increased survival to 1 cm3 tumor in the treated group. Despite PDX-
SBR18 expressing HER2, neratinib alone had no effect neither on growth rate nor on
survival and all animals bore 1 cm3 tumors while still in treatment. Combined treatment
with tamoxifen and neratinib slowed tumor growth and increased survival to 1 cm3 tumor
significantly with respect to untreated group. When compared to tamoxifen alone,
neratinib addition slightly but significantly slowed growth and ameliorated survival to 1
cm3 tumors (fig. 21A).
6.8 Molecular alterations induced by neratinib in luminal B PDX
Downstream pathway analysis was focused on determining neratinib molecular effects
and could not directly show tamoxifen downstream action. Any treatment reduced HER2
and pHER2 expression with respect to untreated mice: tamoxifen alone showed a tiny
effect, whereas neratinib was able to strongly down-modulate HER2 and pHER2 either
alone or in combination with tamoxifen. An additive action of the two drugs was shown
only with regard to pHER2. HER1 was not expressed in PDX-SBR18; HER3 and HER4
were not significantly altered by any treatment and their phosphorylated forms were not
detected by western blot analysis. Downstream of HER-receptors no significant changes
in expression were seen (fig. 21B).
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Figure 21. Neratinib susceptibility and molecular alterations in HER2-enriched PDX
(A) Growth curve and survival to 1 cm3 tumors for PDX-SBR18 untreated animals (black round) and
animals treated with neratinib per os 40mg/kg (red square), tamoxifen (blue rhombus) or their combination
(green triangle). Each point represents the mean of indicated mice. Statistical analysis of growth curve,
Student’s t test, * p<0.05. Statistical analysis of survival curve, Mantel-Cox test, # p< 0.05).
(B) Representative image and western blot analysis of ErbB family members and downstream signaling: the
bar graphs report band intensity normalized over actin for each protein and group. Statistical analysis:
Student’s t test, * p<0.05.
A
B
0 10 20 30 40
0.0
0.5
1.0
1.5
2.0
2.5
* *
Weeks of treatment
Tu
m
o
r 
vo
lu
m
e 
(cm
3 )
0 10 20 30 40
0
20
40
60
80
100
#
Weeks of treatment
%
 
a
n
im
a
l w
ith
 
tu
m
o
r 
 
<
1c
m
3
#
Untreated (n=20)
Neratinib (n=6)
Tamoxifen (n=5)
Tamoxifen+Neratinib
(n=5)
A
108
6.9 Neratinib in trastuzumab-resistant PDX
PDX-BBR4 was initially sensitive to trastuzumab, which significantly slowed tumor
growth and prolonged survival to 1 cm3 tumors with respect to the untreated controls (fig.
22A). Its action appeared limited when compared to neratinib, which halted tumor growth
almost completely (see fig. 20A).
Tumors arisen in trastuzumab-treated mice were transplanted for several consequent
passages in vivo in order to obtain a resistant model. After 6 passages, growth and
survival curves of trastuzumab treated animals overlapped with the one of control mice,
thus indicating that PDX-BBR4 had lost its susceptibility to trastuzumab. Transplanted
once again and treated with neratinib, the tyrosine kinase inhibitor was able to arrest
tumor growth in 100% of mice throughout treatment duration and significantly improve
survival to 1cm3 tumors (fig. 22B).
Figure 22. Neratinib in trastuzumab-resistant PDX
PDX-BBR4 was treated with trastuzumab 4 mg/kg (blue triangle) for six consecutive passages and with
neratinib 40 mg/kg (red square) at next passage in vivo. Untreated mice are shown as solid round.
(A) Tumor growth curve and survival to 1 cm3 tumors for mice bearing PDX-BBR4 treated with
trastuzumab at 1st passage. Each point represents the mean±s.e.m. of indicated mice in the tumor growth
curve.
(B) Tumor growth curve and survival to 1 cm3 tumors for mice bearing BBR-4 PDX treated with
trastuzumab at 6th consecutive passage or with neratinib at following passage in vivo. Each point represents
the mean±s.e.m. of indicated mice in the tumor growth curve.
Statistical analysis of growth curve, Student’s t test, (*) p<0.05 versus control (A) or trastuzumab (B).
Statistical analysis of survival curve, Mantel-Cox test, (#) p< 0.05 versus control (A) or trastuzumab (B).
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6.10 Neratinib in a model of cancer progression
PDX-BBR4 eventually showed signs of progression in vivo. PDX-BBR4 at II passage had
been transplanted into 3 different mice, whose tumors had been amplified in more mice,
giving rise to 6 different sub-lines. Progression event had taken place in only one of the
six different sub-lines at passage XIII and to a lesser extent in another sub-line. In the
progressed sub-line, a statistically significant increase and decrease was respectively
found comparing growth curves and survival to 1 cm3 tumor of passages II-XII and >XIII
(fig. 23A). Moreover, cells dissociated from progressed and not progressed tumors were
injected intravenously to experimentally induce metastasis. Only cells derived from
progressed BBR-4 PDX were able to give rise to overt lung metastasis.
In this spontaneously arisen model of progression, we set out to verify susceptibility to
neratinib. The drug was still able to halt tumor growth to negligible volumes throughout
treatment duration (18 weeks) and to delay significantly time to 1 cm3 tumors with
respect to control group. Nevertheless, after its discontinuation tumors rapidly relapsed
and reached 1 cm3 within 10 weeks in 100% mice (fig. 23B).
Figure 23. Neratinib in cancer progression
(A) Growth curve and survival to 1 cm3 tumors for mice bearing a sub-line of PDX-BBR4 PDX from
passages II to XII (bluish star) and for later passages (green rhombus). Each point represents the
mean±s.e.m. of indicated mice in the growth curve. (B) Growth curve and survival to 1 cm3 tumors of
untreated animals (black round) and animals treated with neratinib per os 40mg/kg (red square). The red
vertical line indicates when the treatment was stopped. Each point represents the mean±s.e.m. of indicated
mice in the growth curve. Statistical analysis of growth curve, Student’s t test, * p<0.05. Statistical analysis
of survival curve, Mantel-Cox test, # p< 0.05).
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6.11 Neratinib in tumors arisen after treatment with neratinib
Tumors arisen in PDX-BBR4 or PDX-SBR45 bearing mice after treatment with neratinib
were transplanted in other animals and treated again with the tyrosine kinase inhibitor.
Both in PDX-BBR4 and PDX-SBR45, neratinib was again able to halt tumor growth to
negligible volumes throughout treatment duration (fig. 24). Moreover, it significantly
improved survival to 1 cm3 tumors in both PDXs. Hence, susceptibility to neratinib was
not lost after the first cycle of therapy and the drug was still effective on relapses.
Figure 24. Neratinib in relapses
PDX-BBR4 (A) and PDX-SBR45 (B) treated with neratinib eventually relapsed. Tumors were transplanted
and treated with neratinib again. Figure reports growth curve and survival to 1 cm3 tumors of untreated
mice (black round) or treated again with neratinib 4 mg/kg (brown square). Each point represents the
mean±s.e.m. of indicated mice for the growth curve. Statistical analysis of growth curve, t Student’s test, *
p<0.05. Statistical analysis of survival curve, Mantel-Cox test, # p< 0.05).
6.12 Are PDXs a possible model for HER2 loss?
HER2 expression has been monitored by PCR, in addition to histological analysis already
reported in table 4, throughout in vivo passages II-XII and in tumor relapses after treatment with
neratinib in all three PDXs.
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In PDX-SBR18, HER2 expression showed some fluctuations from passage II to passage XII,
nevertheless low levels of HER2 expression were always maintained. After neratinib treatment,
HER2 expression appeared to increase slightly but still significantly (fig. 25A).
PDX-BBR4 showed a slightly decreasing HER2 expression after passage II-III, which however
remained unvaried in tumors grown after neratinib treatment was stopped (fig. 25B).
PDX-SBR45 had a constant HER2 expression both throughout in vivo passages. In 2 out of 3
tumors grown after treatment with neratinib, HER2 expression was similar to the one of untreated
controls. One tumor had a much lower HER2 expression with respect to the others; yet, it was still
quite high and no abrupt loss of HER2 expression was observed (fig. 25C).
Overall, despite some decrease and fluctuations, HER2 expression appeared stable and was not
lost neither in passages in vivo nor after treatment with neratinib. Hence, further modifications
and improvements of this model, i.e. through reconstitution of the immune system or
huminization of the micro-environment, will be needed to render PDX useful models of HER2
loss and receptor discordance in general.
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Figure 25. Stability of HER2 expression
HER2 expression was examined by RT-PCR in indicated passages and after neratinib treatment in PDX-
SBR18 (A), PDX-BBR4 (B) and PDX-SBR45 (C). Expression is indicated as ΔCt (CtHER2-CthuTBP).
Statistical analysis: Student’s t test, p< 0.05 (*) versus passages II-III (left graph) or untreated (right graph),
passages IV-V (#), passages VI-VII-VIII (§).
Discussion
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HER2 discordance between primary tumor and metastasis is a clinical issue and occurs in
a pooled meta-analysis percentage of 10.8% (Schrjiver et al., 2018). Some authors have
reported models of loss of neu/HER2 expression in murine or human cell lines,
respectively (Nanni et al., 2000; Song et al., 2014; Creedon et al., 2016). Recently, a
murine model of HER2 loss in mammary tumors has been developed in the Laboratory of
Biology and Immunology of Metastasis directed by Professor Pier-Luigi Lollini. Previous
characterization indicated the association of loss of HER2 expression with spindle-like
morphology, an increased stemness, an EMT profile, a greater aggressiveness in vivo and
superior vasculogenic-like activity in vitro. These observations were in line with
observations in other model of loss of HER2 (Song et al., 2014; Creedon et al., 2016). In
this work, we sought to understand mechanisms underlying loss of HER2 expression and
identify druggable targets in HER2-negative tumors.
Contrasting data are reported in literature on the effect of adjuvant therapy with
trastuzumab in promoting loss of HER2 expression in metastasis (Timmer et al., 2017;
Wang et al., 2017). Moreover, some authors have reported trastuzumab as well as
lapatinib-resistant human mammary cell lines SkBr3 to lose HER2 expression and
acquire mesenchymal phenotype and staminal properties (Korkaya et al., 2012; Creedon
et al., 2016). We firstly set out to assess effect of trastuzumab in HER2labile cell line,
which spontaneously loses HER2 expression in vivo. Long-term treatment with
trastuzumab accelerates emergence of a mesenchymal population out of HER2labile cell
line, which is mesenchymal and endorsed with staminal properties and an EMT profile of
transcription. This cell line, HER2labile TRT, closely resembles HER2loss cells, obtained
from in vivo injection of HER2labile cell line. An acceleration of growth rate was further
observed in tumors induced by HER2labile cells in vivo upon treatment with trastuzumab.
Hence, in our model trastuzumab accelerates emergence of a mesenchymal and staminal
population with an EMT profile of transcription, as previously observed in literature. Of
note, mesenchymal phenotype could not be reverted by trastuzumab subtraction; this is in
line with observations reported in literature that once established, EMT-like phenotype is
sustained by an autocrine loop (Scheel et al., 2014).
Of note, in our model loss of HER2 expression occurs also spontaneously when
HER2labile cells are seeded at low density (≤ 4x104 cell/cm2). Again, in these conditions of
culture cells acquire staminal properties and spindle-like morphology. Thus, density of
cells seems to influence HER2 expression. Indeed, HER2labile cells seem to lose HER2
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whenever they are not densely packed due to low dose, treatment with anti-HER2 drugs
or upon in vivo injection. The observation that even high doses of HER2labile injected
always give rise to HER2-negative tumors further supports the hypothesis that high cell
density is required but not sufficient for HER2labile cells to maintain HER2 expression.
Cell-cell contact appears to be required, as well. A permissive environment for induction
of EMT has been reported to be poor in secreted inhibitors of EMT-linked pathways, such
as SFRP1, DKK1, gremlin and BMPs (Scheel et al., 2014). In our model, SFRP1 resulted
up-regulated in HER2stable cell line, which does not lose HER2 expression; it would be
interesting to study the dynamic of expression of these inhibitors according to cell density
in our model.
At this point, many questions arose about mechanisms underlying loss of HER2
expression. Experiments reported in this thesis clearly allowed us to exclude
immunological selection of HER2-positive cells in vivo, indeed tumors arisen upon
HER2labile injection in immune-compromised mice were HER2-negative as well. Loss of
the transgene in HER2loss cells was also excluded and these cells appeared to harbor the
same copy number of HER2 as HER2labile cells, comparable with SkBr3 human mammary
cancer cells. In our model HER2 is expressed nor at protein nor at mRNA level; hyper-
methylation of promoters is frequent in cancer and leads to silencing of genes down-
stream. We hence checked if this could be the mechanism underlying loss of HER2
expression in HER2loss cells or silencing an EMT program latent in HER2labile cells. Yet,
treatment with a demethylating agent did not restore HER2 expression in HER2loss cells,
but an increase in the HER2-negative population was observed in HER2labile cells treated
with cytotoxic doses of demethylating agent. Hence, mechanism underlying loss of HER2
expression must be further investigated with different demethylating agents or down-
stream in the way from gene to protein.
Recently, a possible hypothesis on the mechanism of resistance to HER2 targeted therapy
involving loss of HER2 expression has also been proposed: in brief, HER2
overexpression would activate an EMT program with increased production of
metalloproteinases, which would in turn cleave HER2 generating p95HER2 isoform,
lacking ECD but still signaling (Nami & Wang, 2017); HER2labile cells express HER2
fragments, which are not detected in HER2stable cells, indeed. Moreover, expression of
Mek has been reported to stabilize HER2 expression in mammary cells detached from
ECM (Khan et al., 2017). These models appear not to be fully applicable in our model,
116
where HER2 is barely not transcribed. Nevertheless, functional studies of secreted EMT
inhibitors, HER2 fragments and Mek through silencing or gene transduction will help us
clarifying molecular mechanisms of HER2 loss.
A second hypothesis arose for emergence of HER2loss cells: HER2labile line could be
representative of a tumor population harboring clones with a heterogeneous expression of
HER2 and HER2loss cells could represent a selected clone rather than an evolution of the
initial HER2labile population. This intra-tumor heterogeneity is indeed observed in 1-40%
of HER2-positive tumors in the clinical practice and represents a clinical issue (Ng et al.,
2015). It is of main importance for the success of HER2 targeted therapies to ensure that
the vast majority of tumor cells are indeed addicted to HER2 expression for the
maintenance of malignant phenotype (Escrìvia-de-Romani et al., 2018). If instead there is
a sub-clone which does not express HER2, it is likely that targeted therapies will clear off
HER2-positive cells but not eradicate the tumor which will relapse as HER2-negative.
This could be the case in our model: in presence of anti-HER2 targeted agents or upon
heavy dilution, equilibrium between the HER2-positive and HER2-negative population
could be outweighed in favor of HER2-negative population. Of note, for many of their
characteristics, i.e. expression of stem cell markers, migratory and metastatic properties,
EMT transcription profile, HER2loss cells can be likened to breast cancer stem cells, so a
further hypothesis could be the selection of a pure population of breast cancer stem cells.
It is of crucial importance to identify druggable targets in HER2-negative metastasis or
recurrences of HER2-positive primary tumors. Therefore, we compared the
transcriptomes of all HER2-positive cell lines in our model with all the HER2-negative
cells. Among HER2-positive cell lines we included, other than the HER2labile cells, the
HER2stable cell line, which did not show any sign of loss of HER2 expression nor
acquisition of mesenchymal or staminal phenotype when treated long term with
trastuzumab (HER2stable TR(N)T), and one of its HER2-positive clones (HER2stable AG3).
Among HER2-negative cell lines, other than HER2loss and HER2labile TR(N)T cells, we
included HER2loss cells treated with trastuzumab, which again did not undergo any
morphological or molecular changes. Inclusion of HER2stable TR(N)T cells and HER2loss
TR(N)T cells permitted us on the one hand to identify genes not linked to lability of
HER2 expression and on the other hand to identify those whose expression is modified
upon trastuzumab binding to HER2.
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Direct comparison of HER2labile and HER2loss cells evidenced only 8 differentially
expressed genes, of which 7 were down-regulated and 1 was up-regulated in HER2loss
cells. Differential expression of Myh14, Cdkn2b, Krt7 and Krt8 and Pla2g7 well mirrors
differences in phenotype between HER2labile and HER2loss cell lines. In turn, we would
expect Wnt7b, Postn an Ifitm10 to be up-regulated in HER2loss, due to their association
with aggressiveness and stemness. Their up-regulation in HER2labile could represent a spy
of these cells being prone to acquisition of mesenchymal characteristics or relying on
different pathways for maintenance of malignant phenotype.
Comparison of transcripts of all HER2-positive and HER2-negative cells in our model
revealed 751 genes differentially expressed between the two subsets. Analysis of protein-
protein interaction and pathway enrichment helped us interpreting these data. Many knots
of interactions emerged in protein-protein interaction analysis reflected presence or
absence of expression of HER2 in the two sets of cells analyzed. Down-regulation of
PTPN1, FGFR1, PAK1, Cul1, IL5 and EFNB1, and their interactors could be expected in
HER2-negative samples as all of them have been reported to be involved in HER2-
mediated oncogenesis or at least up-regulated in HER2 enriched tumors. In the same way,
up-regulation of FN1 and VIM can be expected in HER2-negative samples. Other knots
of interaction and pathways simply mirrored differences in phenotype previously
observed between HER2-negative and HER2-positive cell lines. Up-regulation of cell
migration and angiogenesis in HER2-negative cells is therefore not surprising. On the
other hand, it should be noted that molecules involved in angiogenesis such as VEGFA
and PTGS2 are reported as direct transcriptional target of HER2 (Moasser et al., 2007;
Al-Ameddine et al., 2013). Hence, in HER2-negative cells their up-regulation must be
driven by a different transactivation route. Some knots in protein-protein interaction and
some significantly enriched pathways are linked to mesenchymal nature of HER2-
negative cells. VIM itself is a known marker of mesenchymal differentiation and CDH1
in turn marks epithelial cells: accordingly, they were found up- and down-regulated in
HER2loss cells together with their interactors. Analogously, HER2loss cells showed
increased ECM organization, focal adhesions (i.e. cell-ECM contacts) as well as
decreased protein localization to membrane (i.e. less molecules involved in cell-cell and
cell-ECM adherence and communication) and regulation of actin cytoskeleton. In turn,
HER2-positive cells presented up-regulation of epithelial/luminal differentiation, being
SPTAN1 involved in secretion and Notch1 activated by cell-cell interaction. Except of
118
these descriptive and somewhat expected knots of interaction and enriched pathways,
HER2-negative cells also showed up-regulation of PKB, response to hypoxia,
biosynthesis and protein oligomerization. Most importantly, MYK and PDGFR-B
interactors and PI3K/Akt pathway were found up-regulated in HER2-negative cells: these
pathways are known to be involved in oncogenic transformation and could hence be the
ones sustaining malignant phenotype in HER2-negative cells. Functional studies will now
be required to assess the role of the above reported genes in HER2 loss and as therapeutic
targets.
In this thesis, we focused on PDGFR-B as therapeutic target in HER2loss cells and
sunitinib was chosen as therapeutic agent. Sunitinib is a small-tyrosine-kinase inhibitor
approved by EMA for therapy of renal cell carcinoma and imatinib-resistant GIST
(gastrointestinal stromal tumors). It is a multi-targeted molecule which has been shown to
inhibit PDGFRs, VEGFR and c-Kit. Use of this multi-targeted drug permit us to
simultaneously inhibit PDGFRs and the pathway down-stream VEGFA, the ligand of
VEGFR. Both genes resulted as up-regulated in HER2loss cells, so use of this molecule
appeared doubly indicated.
Sunitinib was effective in halting growth of HER2loss cells both in 2D-adherent and 3D-
non-adherent culture with an IC50 of 4.66 μM. Sunitinib induced a transient change in
HER2loss morphology; nevertheless, HER2 expression remained negative in treated cells.
Sunitinb also reduced ability of HER2loss cells of forming vascular-like tubes in vitro.
Production of IL-6 was also evaluated. IL-6 is a cytokine involved in inflammation and
angiogenesis. High levels of this cytokine have been linked to poor clinical outcome in
breast cancer patients (Korkaya et al. 2012), but different roles of IL-6 have been reported
in breast cancer. IL-6 is part of a pro-inflammatory autocrine loop elicited by HER2,
which triggers activation of Stat3 signaling axis and is critical for tumorigenesis (Hartman
et al., 2011). On the other hand, up-regulation of IL-6 has been reported in a model of
BT474/PTEN- treated long-term trastuzumab (LTT). In this model, IL-6 appeared to
trigger an inflammatory loop which leads towards acquisition of a staminal, basal-like
phenotype and resistance to trastuzumab (Korkaya et al., 2012). Moreover, HER2loss and
HER2labile induced tumors show an abnormal angiogenesis in vivo, characterized by
absence of pericytes, which could be due to an elevated production of IL-6 (Gopinathan
et al., 2015). In our model, IL-6 production was detected in the supernates of HER2stable
and HER2loss but not in HER2labile conditioned media; treatment with sunitinib lowered
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production of IL-6 by HER2loss cells. Production of IL-6 in our model appears to be
paramount of the two roles identified for this cytokine in breast cancer and its pathway
deserves further studies.
In vivo, sunitinib was able to significantly slow down growth of HER2-negative tumors
induced by HER2labile cells but resulted ineffective on the fast growth of tumors induced
by HER2loss cells. Altogether, these data indicate therapeutic targeting of PDGFR-B and
VEGFA by sunitinib in HER2-negative cells is effective in slowing down growth of
HER2-negative tumors through alteration of morphology and EMT profile as well as
down-modulation of angiogenesis and production of IL-6. Nevertheless, inhibition of
PDGFR-B and VEGFR by sunitinb does not eradicate the tumors, thus indicating that
PDGFR-B and VEGFA signaling pathways clearly sustain growth of HER2-negative
cells, but likely they do not represent key drivers of their malignant phenotype.
We took advantage of the collection of mammary patient-derived-xenografts recently
established in the Laboratory of Biology and Immunology of Metastasis to obtain further
models of progression.
Take rate in this collection (7.5%) is similar to the one reported for bigger collections
(10%; Dobrolecki et al., 2017). As frequently observed, our collection is also biased
towards more aggressive subtypes showing the highest rates of PDX attainment and no
PDX attainment for luminal A subtype, the most benign. PDX recapitulate and stably
maintain over time the characteristics of originating tumor at genomic, phenotypic,
histological, molecular and metabolic level and constitute therefore a useful tool for basic
and preclinical research. In our collection, histological parameters and growth rates were
highly stable over serial passages in vivo (at least up to passage XII); yet, for some PDXs,
increasing growth rates and survival to 1 cm3 tumors were observed, thus indicating a
further selection for more malignant clones in vivo.
HER2 expression is not always homogenous and wide-spread in every cell in a tumor.
Clinically, 10% of cells overexpressing HER2 at membrane level or a HER2: CEP ratio
≥2 or a HER2 copy number >6 are enough to classify a breast cancer as HER2-positive
(Loibl & Gianni, 2017). As a consequence, different HER2-positive tumors do not show
the same level of HER2 expression and the same percentage of cells overexpressing
HER2. The two HER2-positive PDX used for the experiments reported in this thesis were
paramount of this inter-tumor heterogeneity. PDX-BBR4 displayed a weak staining in
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10% of cells (2+) with HER2 amplification whereas PDX-SBR45 staining was more
strong and complete (3+). As the originating tumors, the two PDX differed greatly also
for expression of other histopathological features, such as p53, Bcl-2 and HER1
expression. Nevertheless, no major differences were observed in the sensitivity of these
two PDX to neratinib. The pan-HER inhibitor was equally able to halt tumor growth
almost completely throughout treatment duration (15 weeks) and no tumor growth was
observed later on for a very long time (>20 weeks). Some mice remained tumor-free for
more than one year. After this period, relapses were observed both in PDX-BBR4 and
PDX-SBR45; tumors arisen after treatment with neratinib were not resistant to this drug,
though, and treatment with neratinib of relapses, serially transplanted in other mice, was
still effective in halting tumor growth almost completely. Importantly, a model of
resistance to trastuzumab and a model of progression were achieved using HER2-positive
PDX-BBR4 and neratinib showed up its efficacy in halting tumor growth almost
completely in these more challenging models, as well.
Short term treatment with neratinib significantly decreased expression at protein level of
HER1, HER2 and HER4 and their phosphorylated forms. Of note, trends towards HER3
and pHER3 inhibition was also observed underlining reliance of other HER receptors on
HER3; yet, great differences were observed among different treated mice in inhibition of
this receptor. As reported in literature (Canonici et al., 2013), neratinib significantly
inhibited pMAPK and/or pAkt down-stream HER receptors.
PDX-BBR4 gave rise to two models of progression, displaying increased growth rate and
metastatic potential or resistance to trastuzumab. In both models, neratinib was effective
in halting tumor growth. Neratinib has been recently approved by FDA in patients having
completed 1-year adjuvant therapy with trastuzumab. Approval by EMA was more
troublesome and adverse effects were judged not to adequately counterbalance the
relatively small vantage in survival provided by treatment with neratinib. EMA has
therefore limited use of neratinib in triple positive tumors, where it showed a greater
efficacy. Collectively, our data, obtained in ER-/PR- HER2+ PDX, strongly indicate a
great and long-lasting efficacy of neratinib even in trastuzumab-resistance and after
progression and call for further evaluation of neratinib in advanced clinical settings.
We also evaluated neratinib in a luminal B PDX-SBR18, as single therapy or in
combination with tamoxifen, the standard of care for luminal B tumors. Tumor
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originating PDX-SBR18 already showed some HER2 expression (score 0/1+) and in vivo
a clone with slightly higher HER2 expression was selected (score 2+). As partially
expected, neratinib alone was totally ineffective as a single therapy, thus indicating that
this luminal B tumor expresses HER2 but this is not the key pathway sustaining its
proliferation. Of note, PDX-SBR18 has no active signaling down-stream other HER
receptor, as indicated by no detection of pHER forms by western blotting; this of course
limited neratinib action and underscores PDX-SBR18 reliance on different pathways. In
combination with tamoxifen, though, neratinib slightly slowed tumor growth and
increased survival to 1 cm3 tumors with respect to tamoxifen as single agent. This effect
was small, though significant, and this observation copes well with neratinib’s greater
efficacy in triple positive tumors rather than in HER2-positive only. Triple-positive
tumors have been reported to be most likely to resist to endocrine or targeted therapies
due to the fine crosstalk existing between RTKs and hormone receptors in breast normal
and cancer cells. (Iancu et al., 2017). Ample preclinical and clinical justification for
combinatorial therapy targeting both estrogen and HER2 pathways concurrently already
exists (Mehta et al., 2014) and the little effect of the combination of tamoxifen and
neratinib reported on luminal PDX-SBR18, indicate that a dual blockade could ameliorate
prognosis of patients with tumors expressing both HER2 and hormone receptors.
Original scope of this work was to verify if PDX could constitute models of HER2 loss or
even patient’s avatar predicting loss of HER2 expression in patient’s recurrences or
metastasis. The latter is of course not applicable due to low take rates, long times required
for PDX generation and low metastatic rates observed. We checked HER2 expression
both on serial passages in vivo and on tumors grown after treatment with neratinib, but no
abrupt loss of HER2 expression was registered. Hence, further studies will be needed to
evaluate receptor discordance in PDXs: it should be noted that effects of tumor
microenvironment and immune system are difficult to evaluate. A possibility for further
studies would be to reconstitute immune system of immunodeficient mice or to directly
administer cytokines to evaluate their effect on receptor discordance and on stability of
PDX in general.
Conclusion
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Our model of mice transgenic for human HER2 expression has shown that spontaneous or
trastuzumab-induced loss of HER2 expression can progress towards a more aggressive
phenotype, acquisition of EMT, increased stemness and metastatic potential, increased
and but altered angiogenesis as well as resistance to targeted anti-HER2 therapies. Loss of
HER2 expression and worst prognosis is observed in some human HER2-positive tumors
as well. In this murine model, the study of transcriptome of cell lines with different HER2
expression has permitted us to identify pathways related to the modulation of this more
malignant phenotype, which could represent a therapeutic target in case of HER2 loss; in
this perspective, some indications for inhibition of PDGFR-B by sunitinib emerged.
Further functional analysis based on transduction or silencing of significative genes
individuated by transcriptomic analysis will help identifying drivers and therapeutic
targets in HER2loss.
On the other hand, the study of HER2-positive breast carcinoma patient derived
xenografts with different HER2 expression highlighted a different mode of increased
metastasis and resistance to targeted therapies without loss of HER2 expression.
Resistance to trastuzumab in this model was overcome by treatment with neratinib. This
drug was also moderately effective in combination with tamoxifen in slowing down
growth of a PDX HER2-expressing (score 2+) but without HER2 amplification, thus
clinically diagnosed as HER2-negative luminal B.
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